<SEC-DOCUMENT>0001047469-14-008918.txt : 20141106
<SEC-HEADER>0001047469-14-008918.hdr.sgml : 20141106
<ACCEPTANCE-DATETIME>20141106161431
ACCESSION NUMBER:		0001047469-14-008918
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20141106
DATE AS OF CHANGE:		20141106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-192640
		FILM NUMBER:		141200845

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2222060z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg45801_table_of_contents">  Table of Contents</A> <BR>
<A HREF="#bg45802a_main_toc">  Table of Contents</A><BR></font>
</P>
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B>Filed Pursuant to Rule&nbsp;424(b)(5)<BR>
Registration No.&nbsp;333-192640  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1><B>Title of each class of<BR>
securities to be registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount<BR>
to be<BR>
registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed<BR>
maximum<BR>
offering<BR>
price<BR>
per unit</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed<BR>
maximum<BR>
aggregate<BR>
offering price</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
registration fee</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:4pt;text-indent:-4pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>Common Stock, par value $0.001 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76,086</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$16.68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$1,268,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$147.43(1)</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
filing fee is calculated in accordance with Rule&nbsp;457(r) under the Securities Act of 1933, as amended. This "Calculation of Registration Fee"
table shall be deemed to update the "Calculation of Registration Fee" table in the registrant's Registration Statement on Form&nbsp;S-3 (File No.&nbsp;333-192640) in accordance with
Rules&nbsp;456(b) and 457(r) under the Securities Act of 1933, as amended. Estimated solely for purposes of calculating the registration fee pursuant to Rule&nbsp;457(c) under the Securities Act,
based on average of high and low price per share of the common stock as reported on the NASDAQ Global Market on November&nbsp;4, 2014.  </FONT></DD></DL>
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=804571,FOLIO='blank',FILE='DISK116:[14ZCX1.14ZCX45801]AA45801A.;4',USER='HYUNG',CD=';5-NOV-2014;13:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bg45801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Prospectus Supplement<BR>  </B></FONT><FONT SIZE=2>(To prospectus dated December&nbsp;3, 2013) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g148431.jpg" ALT="GRAPHIC" WIDTH="261" HEIGHT="63">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>76,086 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the offer and resale by the selling stockholder identified in this prospectus of up to an aggregate of 76,086 shares of
our common stock. We will not receive any of the proceeds from the sale of the common stock by the selling stockholder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholder identified in this prospectus may offer the shares from time to time through public or private transactions at prevailing market prices or at privately negotiated
prices. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to pay certain expenses in connection with the registration of the shares. The selling stockholder will pay all underwriting discounts and selling commissions, if any, in
connection with the sale of the shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on the NASDAQ Global Market under the symbol "CLDX." The last reported sale price of our common stock on the NASDAQ Global Market on November&nbsp;4, 2014
was $16.58 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Before buying shares of our common stock, you should carefully consider the risk factors described in "Risk Factors" beginning on page&nbsp;S-8
of this prospectus and those contained in the documents incorporated by reference in this prospectus.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved of anyone's investment in
these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The date of this prospectus is November&nbsp;6, 2014. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=262220,FOLIO='blank',FILE='DISK116:[14ZCX1.14ZCX45801]BE45801A.;5',USER='HYUNG',CD=';5-NOV-2014;13:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg45801_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg45801a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG45801A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg45801_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG45801_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus Supplement</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45801_about_this_prospectus_supplement"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About This Prospectus Supplement</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45801_about_this_prospectus_supplement"><FONT SIZE=2><BR>
S-1</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45801_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45801_special_note_regarding_forward-looking_statements"><FONT SIZE=2>S-2</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg45801_prospectus_supplement_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Supplement Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg45801_prospectus_supplement_summary"><FONT SIZE=2>S-3</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg45801_the_offering"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Offering</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg45801_the_offering"><FONT SIZE=2>S-7</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di45801_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di45801_risk_factors"><FONT SIZE=2>S-8</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di45801_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di45801_use_of_proceeds"><FONT SIZE=2>S-8</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di45801_selling_stockholder"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling Stockholder</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di45801_selling_stockholder"><FONT SIZE=2>S-8</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di45801_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan of Distribution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di45801_plan_of_distribution"><FONT SIZE=2>S-9</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di45801_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di45801_legal_matters"><FONT SIZE=2>S-11</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di45801_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di45801_experts"><FONT SIZE=2>S-11</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di45801_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di45801_where_you_can_find_more_information"><FONT SIZE=2>S-12</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#page_di45801_1_12"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Documents By Reference</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#page_di45801_1_12"><FONT SIZE=2>S-12</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da45802_about_this_prospectus"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About This Prospectus</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da45802_about_this_prospectus"><FONT SIZE=2><BR>
1</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da45802_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da45802_prospectus_summary"><FONT SIZE=2>2</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45802_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45802_special_note_regarding_forward-looking_statements"><FONT SIZE=2>4</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45802_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45802_risk_factors"><FONT SIZE=2>5</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45802_ratios_of_combined_fixed_charg__rat02955"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratios of Combined Fixed Charges and Preferred Stock Dividends to Earnings</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45802_ratios_of_combined_fixed_charg__rat02955"><FONT SIZE=2>6</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45802_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45802_use_of_proceeds"><FONT SIZE=2>7</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45802_selling_securityholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling Securityholders</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45802_selling_securityholders"><FONT SIZE=2>7</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45802_descriptions_of_securities_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Securities We May Offer</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45802_descriptions_of_securities_we_may_offer"><FONT SIZE=2>8</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc45802_description_of_common_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Common Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc45802_description_of_common_stock"><FONT SIZE=2>9</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_description_of_preferred_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Preferred Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_description_of_preferred_stock"><FONT SIZE=2>10</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_description_of_warrants"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Warrants</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_description_of_warrants"><FONT SIZE=2>13</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_description_of_depositary_shares"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Depositary Shares</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_description_of_depositary_shares"><FONT SIZE=2>15</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_description_of_units"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Units</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_description_of_units"><FONT SIZE=2>16</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan of Distribution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_plan_of_distribution"><FONT SIZE=2>17</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_legal_matters"><FONT SIZE=2>19</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_experts"><FONT SIZE=2>19</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_where_you_can_find_more_information"><FONT SIZE=2>19</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de45802_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Certain Documents by Reference</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de45802_incorporation_of_certain_documents_by_reference"><FONT SIZE=2>20</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=948472,FOLIO='S-i',FILE='DISK116:[14ZCX1.14ZCX45801]BG45801A.;3',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de45801_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg45801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de45801_about_this_prospectus_supplement"> </A>
<A NAME="toc_de45801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS SUPPLEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this prospectus supplement, "Celldex," "we," "us," "our" or "ours" refer to Celldex Therapeutics,&nbsp;Inc. and its consolidated
subsidiary. References to "Selling Stockholder" refer to the holder of our common stock listed in this prospectus supplement under the heading "Selling Stockholder." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement and the accompanying prospectus relate to the offering of shares of our common stock. Before buying any of the shares of common stock offered hereby, we urge
you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated herein by reference as described under the headings "Where You Can Find
More Information" and "Incorporation of Documents by Reference." These documents contain important information that you should consider when making your investment decision. This prospectus supplement
contains information about the common stock offered hereby and may add, update or change information in the accompanying prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus. Neither we nor the selling
stockholder have authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor the selling stockholder are making offers to sell or solicitations to buy our common stock in any jurisdiction in which an offer or solicitation is not authorized or in
which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information in this
prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information that we have
incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus or
any related free writing prospectus, or any sale of a security. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
document is in two parts. The first part is this prospectus supplement, which adds to and updates information contained in the accompanying prospectus. The second part, the
prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To
the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus, you should rely on the information in this
prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed
as exhibits to the registration statement of which this prospectus is a part or as exhibits to documents incorporated by reference herein, and you may obtain copies of those documents as described
below under the headings "Where You Can Find More Information" and "Incorporation of Documents by Reference." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=926425,FOLIO='S-1',FILE='DISK116:[14ZCX1.14ZCX45801]DE45801A.;3',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<A NAME="page_de45801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de45801_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_de45801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements
about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made
through the use of words or phrases such as "anticipate," "estimate," "plans," "projects," "continuing," "ongoing," "expects," "management believes," "we believe," "we intend" and similar words or
phrases. Accordingly, these statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking
statements are qualified in their entirety by reference to the risk factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking
statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management's expectations and assumptions at the time the
statements are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the forward-looking statements for many reasons including
the factors described in the section entitled "Risk Factors" in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. We undertake no obligation to publicly revise
any forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and
risks we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in
this prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=796529,FOLIO='S-2',FILE='DISK116:[14ZCX1.14ZCX45801]DE45801A.;3',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg45801_1_3"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg45801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg45801_prospectus_supplement_summary"> </A>
<A NAME="toc_dg45801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUPPLEMENT SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary of our business highlights some of the information contained elsewhere in or incorporated
by reference into this prospectus supplement. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this
prospectus supplement and the accompanying prospectus, including the documents incorporated by reference, which are described under "Incorporation of Documents by Reference" and
"Where You Can Find More Information" in this prospectus supplement. You should also carefully consider the matters discussed in the section of this prospectus supplement entitled "Risk Factors" and
in the accompanying prospectus and in other periodic reports incorporated by reference herein.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat
diseases. Our drug candidates are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are
using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that
modify undesirable activity by the body's own proteins or cells. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead drug candidates include rindopepimut (also referred to as CDX-110) and glembatumumab vedotin (also referred to as CDX-011). Rindopepimut is a targeted immunotherapeutic in a
pivotal Phase&nbsp;3 study for the treatment of front-line glioblastoma and a Phase&nbsp;2 study for the treatment of recurrent glioblastoma. Glembatumumab vedotin is a targeted antibody-drug
conjugate in a randomized study for the treatment of triple negative breast cancer designed to obtain accelerated approval. We also have a number of earlier stage drug candidates in clinical
development, including varlilumab (also referred to as CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications, CDX-301, an immune cell mobilizing agent and dendritic cell
growth factor and CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells, or APC, for cancer indications. Our drug candidates address market opportunities for which we believe
current therapies are inadequate or non-existent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are building a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Our program assets provide us with
the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach allows us to
maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are
using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that
modify undesirable activity by the body's own proteins or cells. A number of our immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. We expect that
a large percentage of our research and development expenses will be incurred in support of our current and future clinical trial programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Rindopepimut (CDX-110)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rindopepimut is an immunotherapeutic drug that targets the tumor-specific molecule epidermal growth factor receptor variant III, or
EGFRvIII. EGFRvIII is a mutated form of the epidermal growth factor receptor, or EGFR, that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell
growth. EGFRvIII is expressed in approximately 30% of glioblastoma, or GBM, tumors, the most common and aggressive form of brain cancer. Rindopepimut is composed of </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=543102,FOLIO='S-3',FILE='DISK116:[14ZCX1.14ZCX45801]DG45801A.;6',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<A NAME="page_dg45801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:times;"><FONT SIZE=2>the
EGFRvIII peptide linked to a carrier protein called Keyhole Limpet Hemocyanin, or KLH, and administered together with the adjuvant GM-CSF. The Food and Drug Administration, or FDA, and the
European Medicines Agency, or EMA, have both granted orphan drug designation for rindopepimut for the treatment of EGFRvIII expressing GBM. The FDA has also granted Fast Track designation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the results of the three prior Phase&nbsp;2 trials, in December 2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase&nbsp;3 study of rindopepimut
in patients with surgically resected EGFRvIII-positive GBM. Patients are randomized after the completion of surgery and standard chemoradiation treatment. The treatment regimen includes a rindopepimut
priming phase post-radiation followed by standard of care temozolomide, or TMZ, and a rindopepimut maintenance therapy phase. Patients are treated until disease progression or intolerance to therapy.
The primary objective of the study is to determine whether rindopepimut plus adjuvant GM-CSF improves the overall survival of patients with newly diagnosed EGFRvIII-positive GBM with minimal residual
disease post resection and traditional chemo-radiation when compared to treatment with TMZ and a control injection of KLH. KLH is a component of rindopepimut and was selected due to its ability to
generate a similar injection site reaction to that observed with rindopepimut. ACT IV is enrolling patients at over 200 centers worldwide and is expected to accrue approximately 700 patients to reach
the required 374 patients with minimal residual disease needed for analysis of the primary endpoint, overall survival. In October, target enrollment of 700 patients was reached. Given the lack of
treatment options for patients with GBM, additional patients with the EGFRvIII mutation remaining in screening will be
allowed to enroll into the study before enrollment is formally completed by year end 2014. Interim analyses will be conducted by an independent Data Safety and Monitoring Board at 50% and 75% of
events (deaths). The first interim is expected in the mid-2015 and will provide insight into the event rate to inform estimates regarding timing for the second interim and final data read out. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2011, we also initiated ReACT, a Phase&nbsp;2 study of rindopepimut in combination with bevacizumab in patients with recurrent EGFRvIII-positive GBM. ReACT was initially
planned to enroll approximately 95 patients in a first or second relapse of GBM following receipt of standard therapy at approximately 25 sites across the United States. In August 2013, we announced
the addition of an expansion cohort of approximately 75 patients (Group 2C) to better characterize the potential activity of rindopepimut in this refractory patient population. This decision was based
on early evidence of anti-tumor activity, including stable disease, tumor shrinkage and investigator-reported response. As amended, the ReACT study will now enroll approximately 170 patients across
three groups. Approximately 70 patients (Group 1)&nbsp;who have yet to receive bevacizumab will be randomized to receive either rindopepimut and bevacizumab or a control injection of KLH and
bevacizumab in a blinded fashion. Another 100 patients, including the expansion cohort of 75 patients, who are refractory to bevacizumab having received bevacizumab in either the frontline or
recurrent setting with subsequent progression will receive rindopepimut plus bevacizumab in a single treatment arm. Study endpoints include 6&nbsp;month progression free survival rate, objective
response rate, or ORR, overall survival and safety and tolerability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2013, we reported interim data from our ongoing Phase&nbsp;2 ReACT study. Rindopepimut plus bevacizumab was very well tolerated (dosing up to 13+ months) and the results
demonstrated promising signs of clinical activity in advanced patient populations, including evidence of anti-tumor activity (tumor shrinkage, objective response and stable disease). Strong immune
response correlated with improved outcome. In bevacizumab-na&iuml;ve patients treated with both rindopepimut and bevacizumab, a strong survival trend has also been seen to date versus the
control group. We are currently completing the study and anticipate presenting additional data from the study at the 19<SUP>th</SUP>&nbsp;Annual Scientific Meeting and Education Day of the
Society for Neuro-Oncology in November 2014. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=7,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=109820,FOLIO='S-4',FILE='DISK116:[14ZCX1.14ZCX45801]DG45801A.;6',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<A NAME="page_dg45801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:times;"><FONT SIZE=2><B> Glembatumumab Vedotin (CDX-011)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glembatumumab vedotin is an antibody-drug conjugate for the treatment of patients with glycoprotein NMB, referred to as gpNMB,
expressing advanced, refractory breast cancer. Glembatumumab vedotin targets the protein gpNMB, which is over-expressed in a variety of cancers, including breast cancer and melanoma. The FDA has
granted Fast Track designation to glembatumumab vedotin for the treatment of advanced, refractory/resistant gpNMB-expressing breast cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2012, we announced final results from the EMERGE study, a randomized, multi-center Phase&nbsp;2b study of glembatumumab vedotin in 122 patients with heavily pre-treated,
advanced, gpNMB positive breast cancer. Patients were randomized (2:1) to receive either glembatumumab vedotin or single-agent Investigator's Choice, or IC, chemotherapy. Patients randomized to
receive IC were allowed to cross over to receive glembatumumab vedotin following disease progression. Activity endpoints included response rate and progression-free survival and overall survival. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2013, we initiated METRIC, a randomized, controlled study of glembatumumab vedotin in patients with triple negative breast cancer that over-express gpNMB in the United
States, Canada and Australia. The study was originally designed to obtain accelerated approval. Feedback from clinical investigators conducting the study indicated that the eligibility criteria for
study entry were limiting their ability to enroll patients they felt were clinically appropriate on study. In addition, we have spoken to country-specific members of the EMA and believe a significant
opportunity exists to expand the study into the European Union, or EU. Based on these factors, we have amended the METRIC study and expanded patient entry criteria to position it for full marketing
approval with global regulators, including the EMA, and to support improved enrollment in the study. The primary endpoint will be progression free survival as progression free survival is an
established endpoint for full approval registration studies in this patient population in both the US and the EU. The sample size of 300 patients and the secondary endpoint of overall survival remain
unchanged. The Company is implementing these changes in parallel to regulatory discussions to maintain momentum at open clinical trial sites. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Varlilumab  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Varlilumab is a human monoclonal antibody that targets CD27, a potentially important target for immunotherapy of various cancers. CD27
acts downstream from CD40 and may provide a novel way to regulate the immune responses. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias.
Varlilumab is an agonist antibody designed to have two potential therapeutic mechanisms. Varlilumab has been shown to activate immune cells that can target and eliminate cancerous cells in
tumor-bearing mice and to directly kill or inhibit
the growth of CD27-expressing lymphomas and leukemias in vitro and in vivo. Both mechanisms have been seen even at low doses in preclinical models. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are conducting an open label Phase&nbsp;1 study of varlilumab in patients with selected malignant solid tumors or hematologic cancers at multiple clinical sites in the United
States. We presented data from this Phase&nbsp;1 study in June 2014. Varlilumab was very well tolerated and induced immunologic activity in patients that is consistent with both its mechanism of
action and preclinical models. Based on these data, we intend to initiate new studies of varlilumab in combination with various agents in the fourth quarter of 2014. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2014, we entered into a clinical trial collaboration with BMS to evaluate the safety, tolerability and preliminary efficacy of varlilumab and nivolumab, BMS's PD-1 immune
checkpoint inhibitor, in a Phase&nbsp;1/2 study. Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer, metastatic melanoma, ovarian,
colorectal and squamous cell head and neck cancers. The Phase&nbsp;1/2 study is expected to begin in the fourth quarter of 2014. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=8,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=860165,FOLIO='S-5',FILE='DISK116:[14ZCX1.14ZCX45801]DG45801A.;6',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<A NAME="page_dg45801_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Multiple
efforts are underway to finalize designs and plans for additional Phase&nbsp;2 studies of varlilumab and we will provide updates on these studies as they are initiated,
included but not limited to: a Phase&nbsp;1/2 study of varlilumab and ipilumumab in patients with metastatic melanoma (plus CDX-1401 in NY-ESO positive patients); a Phase&nbsp;1/2 of varlilumab
plus sunitinib in renal cell carcinoma; and a Phase&nbsp;1/2 study of varlilumab plus a mek pathway agent (followed sequentially by a checkpoint inhibitor) for patients with B-raf mutated metastatic
melanoma. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Other Clinical and Pre-Clinical Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have several other programs in clinical and pre-clinical development. The status of the other programs that we currently believe are
significant to our business is summarized in the table below: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:67pt;"><FONT SIZE=1><B>Product Candidate

<!-- COMMAND=ADD_SCROPPEDRULE,67pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stage of Clinical Development </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Allogeneic Hematopoietic Stem Cell Transplantation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Pilot</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>CDX-014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Ovarian and renal cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in 1983. On October&nbsp;1, 2009, a wholly-owned subsidiary of Celldex merged with and into
CuraGen Corporation. On December&nbsp;31, 2009, CuraGen Corporation was merged with and into Celldex and the separate existence of CuraGen ceased. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
principal executive offices are located at Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, New Jersey 08827 and our telephone number is (908)&nbsp;200-7500.
Our corporate website is www.celldextherapeutics.com. The information on our website is not incorporated by reference into this prospectus. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=9,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=123181,FOLIO='S-6',FILE='DISK116:[14ZCX1.14ZCX45801]DG45801A.;6',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<A NAME="page_dg45801_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg45801_the_offering"> </A>
<A NAME="toc_dg45801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Common stock offered by the selling stockholder</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Up to 76,086 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Common stock outstanding</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>89,589,105 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Manner of offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>The selling stockholder will determine when and how they sell the common stock offered in this prospectus, as described in "Plan of Distribution."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>We will not receive any of the proceeds from the sale of the shares of common stock being offered under this prospectus. See "Use of Proceeds."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>Investing in our common stock involves a high degree of risk. Please read the information contained in and incorporated by reference under the heading "Risk Factors" on page&nbsp;S-8 of this prospectus,
 and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>NASDAQ Global Market common stock symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>CLDX</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=10,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=998481,FOLIO='S-7',FILE='DISK116:[14ZCX1.14ZCX45801]DG45801A.;6',USER='LPALLES',CD=';5-NOV-2014;13:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di45801_1_8"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg45801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_risk_factors"> </A>
<A NAME="toc_di45801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks and other information we
include or incorporate by reference in this prospectus and the accompanying prospectus. In particular, you should consider the risk factors under the heading "Risk Factors" included in our most recent
Annual Report on Form&nbsp;10-K, as may be revised or supplemented by our subsequent Quarterly Reports on Form&nbsp;10-Q or Current Reports on Form&nbsp;8-K, each of which are on file with the
SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we
have described are not the only ones facing our company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect our business operations. Our
business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and
you may lose all or part of your investment. This prospectus is qualified in its entirety by these risk factors.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_use_of_proceeds"> </A>
<A NAME="toc_di45801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will not receive any proceeds from the sale of shares of our common stock by the selling stockholder pursuant to this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_selling_stockholder"> </A>
<A NAME="toc_di45801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  SELLING STOCKHOLDER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the possible resale by the selling stockholder of up to 76,086 shares of our common stock. We are
registering the shares of common stock in order to permit the selling stockholder to offer the shares for resale from time to time. Except as described below, the selling stockholder has not had any
material relationship with us within the past three years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information as of November&nbsp;4, 2014, regarding beneficial ownership (as determined under Section&nbsp;13(d) of the Securities Exchange Act of 1934,
as amended, and the rules and regulations thereunder) of the selling stockholder that is offering shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus.
When we refer to the "selling stockholder" in this prospectus supplement, we mean those person listed in the table below. We will not receive any proceeds from the sale of shares of our common stock
by the selling stockholder. We will also bear the costs, other than underwriting discounts and commissions, associated with the sale of shares of common stock by the selling stockholder. See "Plan of
Distribution." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
address for the selling stockholder is c/o Biosyn Corporation, 5939 Darwin Court, Suite&nbsp;114, Carlsbad, CA 92008. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="134pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Beneficial Ownership<BR>
Prior To This Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Beneficial Ownership<BR>
After This Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum Number of Shares<BR>
to be offered </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:90pt;"><FONT SIZE=1><B>Selling Stockholder name

<!-- COMMAND=ADD_SCROPPEDRULE,90pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Biosyn Corporation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>152,172</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,086</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,086</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
upon 89,589,105 shares of our common stock outstanding as of October&nbsp;31, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Less
than 1%.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=376598,FOLIO='S-8',FILE='DISK116:[14ZCX1.14ZCX45801]DI45801A.;6',USER='DPERRY',CD=';5-NOV-2014;13:56' -->
<A NAME="page_di45801_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Material Relationships with Selling Stockholder  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;15, 2014, we entered into a Third Amended and Restated Supply Agreement, or the Amended Supply Agreement, with Biosyn
Corporation, or Biosyn. Pursuant to the terms of the Amended Supply Agreement, Biosyn will manufacture and supply to Celldex, Biosyn's proprietary formulation of hemocyanin products, including keyhole
limpet hemocyanin, or KLH, for use in connection with the development, manufacture or commercial sale of Celldex's lead product rindopepimut. Celldex has agreed to order KLH exclusively from Biosyn.
As part of the agreement, Biosyn granted to Celldex a non-exclusive, perpetual, royalty-free license to KLH to research, develop, make, have made, sell, use, offer for sale, export and import
rindopepimut. Biosyn will support all regulatory filings of Celldex and allow Celldex to cross-reference Biosyn's Drug Master File for KLH as required by U.S. and foreign equivalent agencies. The
Amended Supply Agreement provides for an initial term of fifteen years and further terms of five years each. The Amended Supply Agreement may be terminated without cause by either party upon written
notice of termination at least six months prior to the end of the initial term or further term, as applicable. Celldex may also terminate the Amended Supply Agreement upon sixty days' notice in the
event Celldex ceases further development of rindopepimut. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Amended Supply Agreement, Celldex and Biosyn entered into a Subscription Agreement pursuant to which, on October&nbsp;15, 2014, Celldex issued to Biosyn, as
additional compensation, 152,172 shares of common stock of Celldex, 50% of which are subject to a one-year lock-up agreement. Celldex agreed to register the remaining 50% of such shares, or the
registrable shares, and to maintain such registration until the earlier of (i)&nbsp;the date that all registrable shares have been sold, (ii)&nbsp;the date that all registrable Shares can be sold
publicly without restriction or limitation under Rule&nbsp;144 (including, without limitation, the requirement to be in compliance with Rule&nbsp;144(c)(1)) or (iii)&nbsp;the date that is two
(2)&nbsp;years following the date of the Amended Supply Agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_plan_of_distribution"> </A>
<A NAME="toc_di45801_4"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are registering for resale by the selling stockholder a total of 76,086 shares of common stock. We will not receive any of the
proceeds from the sale by the selling stockholder of the shares of common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholder may sell all or a portion of the shares of common stock held by them and offered hereby from time to time directly or through one or more underwriters,
broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the selling stockholder will be responsible for underwriting discounts or commissions or
agent's commissions. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time
of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions, pursuant to one or more of the following
methods:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of
sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the over-the-counter market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in transactions otherwise than on these exchanges or systems or in the over-the-counter market; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through the writing or settlement of options, whether such options are listed on an options exchange or otherwise; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1003411,FOLIO='S-9',FILE='DISK116:[14ZCX1.14ZCX45801]DI45801A.;6',USER='DPERRY',CD=';5-NOV-2014;13:56' -->
<A NAME="page_di45801_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of
the block as principal to facilitate the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an exchange distribution in accordance with the rules of the applicable exchange; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> privately negotiated transactions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> short sales; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> broker-dealers may agree with the selling stockholder to sell a specified number of such shares at a stipulated price per
share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a combination of any such methods of sale; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other method permitted pursuant to applicable law. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholder may also sell shares of common stock under Rule&nbsp;144 promulgated under the Securities Act of 1933, as amended, if available, rather than under this
prospectus. In addition, the selling stockholder may transfer the shares of common stock by other means not described in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the selling stockholder effect such transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents
may receive commissions in the form of discounts, concessions or commissions from the selling stockholder or commissions from purchasers of the shares of common stock for whom they may act as agent or
to
whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved). In connection with sales of the shares of common stock or otherwise, the selling stockholder may enter into hedging transactions with broker-dealers, which may in turn engage in short sales
of the shares of common stock in the course of hedging in positions they assume. The selling stockholder may also sell shares of common stock short and deliver shares of common stock covered by this
prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholder may also loan or pledge shares of common stock to broker-dealers that
in turn may sell such shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholder may pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured
obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule&nbsp;424(b)(3)
or other applicable provision of the Securities Act amending, if necessary, the list of selling stockholder to include the pledgee, transferee or other successors in interest as selling stockholder
under this prospectus. The selling stockholder also may transfer and donate the shares of common stock in other circumstances in which case the transferees, donees, pledgees or other successors in
interest will be the selling beneficial owners for purposes of this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent required by the Securities Act and the rules and regulations thereunder, the selling stockholder and any broker-dealer participating in the distribution of the shares of
common stock may be deemed to be "underwriters" within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to
be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of common stock is made, a prospectus supplement, if required, will be distributed,
which will set forth the aggregate amount of shares of common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions
and other terms </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=115056,FOLIO='S-10',FILE='DISK116:[14ZCX1.14ZCX45801]DI45801A.;6',USER='DPERRY',CD=';5-NOV-2014;13:56' -->
<A NAME="page_di45801_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>constituting
compensation from the selling stockholder and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the
shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurance that the selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement of which this prospectus
supplement forms&nbsp;a part. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholder and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended, and the rules
and regulations thereunder, including, without limitation, to the extent applicable, Regulation&nbsp;M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of
common stock by the selling stockholder and any other participating person. To the extent applicable, Regulation&nbsp;M may also restrict the ability of any person engaged in the distribution of the
shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the marketability of the shares of common stock and the ability
of any person or entity to engage in market-making activities with respect to the shares of common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will indemnify the selling stockholder against liabilities, including some liabilities under the Securities Act in accordance with certain agreements with the selling stockholder, or
the selling stockholder will be entitled to contribution. We may be indemnified by the selling stockholder against civil liabilities, including liabilities under the Securities Act that may arise from
any written information furnished to us by the selling stockholder specifically for use in this prospectus, in accordance with certain agreements with the selling stockholder, or we may be entitled to
contribution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
sold under the registration statement, of which this prospectus supplement is a part, the shares of common stock will be freely tradeable in the hands of persons other than our
affiliates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_legal_matters"> </A>
<A NAME="toc_di45801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the securities being offered hereby will be passed upon by Lowenstein Sandler&nbsp;LLP, Roseland, New Jersey. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_experts"> </A>
<A NAME="toc_di45801_6"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements and management's assessment of the effectiveness of internal control over financial reporting (which is
included in Management's Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to our Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2013 have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=14,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=138998,FOLIO='S-11',FILE='DISK116:[14ZCX1.14ZCX45801]DI45801A.;6',USER='DPERRY',CD=';5-NOV-2014;13:56' -->
<A NAME="page_di45801_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_where_you_can_find_more_information"> </A>
<A NAME="toc_di45801_7"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act of which this
prospectus forms&nbsp;a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of certain agreements or
documents that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is
qualified in all respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated by reference in this
prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at </FONT> <FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>.
The SEC's website contains reports, proxy statements and other information regarding issuers, such as Celldex
Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC's Public Reference Room, located at 100&nbsp;F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. We make available free of charge through our web site our Annual
Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, Proxy Statements on Schedule&nbsp;14A and all amendments to those reports as soon as reasonably
practicable after such material is electronically filed with or furnished to the SEC. Our website address is </FONT><FONT SIZE=2><I>http://www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. Please
note that our website address is provided as an inactive textual reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement,
and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di45801_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_di45801_8"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" into this prospectus the information we have filed with the SEC, which means that we
can disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by
reference into this prospectus the information
contained in the documents listed below, which is considered to be a part of this prospectus:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2013, filed with the SEC on
March&nbsp;3, 2014 (including the portions of our Proxy Statement on Schedule&nbsp;14A, filed with the SEC on April&nbsp;9, 2014, incorporated by reference therein); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2014, June&nbsp;30, 2014 and
September&nbsp;30, 2014, filed on May&nbsp;1, 2014, August&nbsp;7, 2014 and November&nbsp;5, 2014, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Current Reports on Form&nbsp;8-K filed with the SEC on March&nbsp;3, 2014, April&nbsp;8, 2014, May&nbsp;1,
2014, May&nbsp;14, 2014, May&nbsp;29, 2014, August&nbsp;6, 2014, October&nbsp;20, 2014, November&nbsp;4, 2014 and November 6, 2014 (in each case, not including any information furnished
under Items&nbsp;2.02 or 7.01 of Form&nbsp;8-K, including the related exhibits, which information is not incorporated by reference herein); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of our Common Stock contained in our registration statement on Form&nbsp;8-A, filed with the SEC on
September&nbsp;22, 1986 under Section&nbsp;12 of the Securities Exchange Act, and any amendments or reports filed for the purpose of updating such description; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of the rights to purchase our Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock
contained in our registration statement on Form&nbsp;S-4, filed with the SEC on </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=15,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=973690,FOLIO='S-12',FILE='DISK116:[14ZCX1.14ZCX45801]DI45801A.;6',USER='DPERRY',CD=';5-NOV-2014;13:56' -->
<A NAME="page_di45801_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg45801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>December&nbsp;21,
2007, our registration statement on Form&nbsp;8-A filed with the SEC on November&nbsp;8, 2004, our registration statement on Form&nbsp;8-A/A filed with the SEC on
October&nbsp;22, 2007, our registration statement on Form&nbsp;8-A/A filed with the SEC on March&nbsp;7, 2008, and any amendment or report filed with the SEC for the purposes of updating such
descriptions. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (a)&nbsp;after the initial filing date of the registration
statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a
post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold. The most
recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this prospectus,
commencing on the date on which the document is filed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item&nbsp;2.02 or 7.01 of Form&nbsp;8-K. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by
reference other than exhibits to those documents. Requests should be addressed to: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Celldex Therapeutics,&nbsp;Inc.</B></FONT><FONT SIZE=2><BR>
Attention: Investor Relations<BR>
Perryville III Building, 53 Frontage Road, Suite&nbsp;220,<BR>
Hampton, New Jersey 08827<BR>
Telephone number: (908)&nbsp;200-7500 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=16,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=49236,FOLIO='S-13',FILE='DISK116:[14ZCX1.14ZCX45801]DI45801A.;6',USER='DPERRY',CD=';5-NOV-2014;13:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bg45802a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Preferred Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Warrants  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Depositary Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Units  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Celldex Therapeutics,&nbsp;Inc. or any selling securityholders may offer, issue and sell from time to time, together or separately, in one or more offerings,
any combination of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>our common stock, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>our preferred stock, which we may issue in one or more series, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>warrants, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>depositary shares, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>units. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus provides a general description of the securities we may offer. Each time we or any selling securityholders sell securities, we will provide specific terms of the securities offered in
a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus and the accompanying prospectus
supplement, as well as the documents incorporated or deemed incorporated by reference in this prospectus, carefully before you make your investment decision. Our common stock is traded on the NASDAQ
Global Market under the symbol "CLDX." On November&nbsp;29, 2013, the last reported sale price of our common stock on the NASDAQ Global Market was $27.76 per share. You are urged to obtain current
market quotations of the common stock. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus may not be used to sell securities unless accompanied by a prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
or any selling securityholders may offer to sell these securities on a continuous or delayed basis, through agents, dealers or underwriters, or directly to purchasers. The prospectus supplement for
each offering of securities will describe in detail the plan of distribution for that offering. If our agents or any dealers or underwriters are involved in the sale of the securities, the applicable
prospectus supplement will set forth the names of the agents, dealers or underwriters and any applicable commissions or discounts. Our net proceeds from
the sale of securities will also be set forth in the applicable prospectus supplement. For general information about the distribution of securities offered, please see "Plan of Distribution" in this
prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Investing in our securities involves risks. Before making an investment decisions, you should carefully review the information contained in this prospectus under the heading
"Risk Factors" beginning on page&nbsp;5 of this prospectus.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION OR REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The date of this prospectus is December&nbsp;3, 2013. </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=17,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=987053,FOLIO='blank',FILE='DISK121:[14ZCX2.14ZCX45802]BE45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bg45802a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG45802A_main_toc"></A>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Table of Contents  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> <A NAME="BG45802_TOC"></A>  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="17pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#da45802_about_this_prospectus"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#da45802_about_this_prospectus"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#da45802_prospectus_summary"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#da45802_prospectus_summary"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc45802_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc45802_special_note_regarding_forward-looking_statements"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc45802_risk_factors"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc45802_risk_factors"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc45802_ratios_of_combined_fixed_charg__rat02955"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIOS OF COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc45802_ratios_of_combined_fixed_charg__rat02955"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc45802_use_of_proceeds"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc45802_use_of_proceeds"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc45802_selling_securityholders"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELLING SECURITYHOLDERS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc45802_selling_securityholders"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc45802_descriptions_of_securities_we_may_offer"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTIONS OF SECURITIES WE MAY OFFER</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc45802_descriptions_of_securities_we_may_offer"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#dc45802_description_of_common_stock"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dc45802_description_of_common_stock"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>9</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_description_of_preferred_stock"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_description_of_preferred_stock"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_description_of_warrants"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_description_of_warrants"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_description_of_depositary_shares"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEPOSITARY SHARES</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_description_of_depositary_shares"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>15</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_description_of_units"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF UNITS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_description_of_units"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>16</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_plan_of_distribution"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_plan_of_distribution"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>17</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_legal_matters"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_legal_matters"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_experts"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_experts"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_where_you_can_find_more_information"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_where_you_can_find_more_information"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><A HREF="#de45802_incorporation_of_certain_documents_by_reference"><p style="font-family:arial;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#de45802_incorporation_of_certain_documents_by_reference"><p align=right style="font-family:arial;margin-left:14pt;text-indent:-14pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>20</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=744237,FOLIO='blank',FILE='DISK121:[14ZCX2.14ZCX45802]BG45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_da45802_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2>
<A HREF="#bg45802a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45802_about_this_prospectus"> </A>
<A NAME="toc_da45802_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a "shelf" registration process. Under this shelf registration
process, we or any selling securityholders may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus.
You should read the registration statement and the accompanying exhibits for further information. The registration statement, including the exhibits and the documents incorporated or deemed
incorporated herein by reference, can be read and are available to the public over the Internet at the SEC's website at </FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2> as described
under the heading "Where You Can Find More Information." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus provides you with a general description of the securities we or any selling securityholders may offer. Each time we or any selling securityholders sell securities pursuant to this
prospectus, we will provide a prospectus supplement containing specific information about the terms of a particular offering by us or any selling securityholders. That prospectus supplement may
include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may add, update or change information in this prospectus. If the
information in the prospectus is inconsistent with a prospectus supplement, you should rely on the information in that prospectus supplement. You should read both this prospectus and, if applicable,
any prospectus supplement. See "Where You Can Find More Information" for more information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized any dealer, salesman or other person to give any information or to make any
representation other than those contained or incorporated by reference in this prospectus or any prospectus supplement. You must not rely upon any information or representation not contained or
incorporated by reference in this prospectus or any prospectus supplement. This prospectus and any prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any
securities other than the registered securities to which they relate, nor do this prospectus and any prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities
in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus or any
prospectus supplement is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent
to the date of the document incorporated by reference, even though this prospectus and any prospectus supplement is delivered or securities are sold on a later date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Unless this prospectus indicates otherwise or the context otherwise requires, the terms "we," "our," "us," "Celldex" or the "Company" as used in this prospectus refer to Celldex
Therapeutics,&nbsp;Inc. and its subsidiaries, except that such terms refer to only Celldex Therapeutics,&nbsp;Inc. and not its subsidiaries in the sections entitled "Description of Common Stock,"
"Description of Preferred Stock," "Description of Warrants," "Description of Depositary Shares," and "Description of Units."</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=857484,FOLIO='1',FILE='DISK121:[14ZCX2.14ZCX45802]DA45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<A NAME="page_da45802_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da45802_prospectus_summary"> </A>
<A NAME="toc_da45802_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Company Overview  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer
and other difficult-to-treat diseases. Our lead drug candidates include rindopepimut (CDX-110), an immunotherapeutic vaccine in a pivotal Phase&nbsp;3 study for the treatment of front-line
glioblastoma and a Phase&nbsp;2 study for the treatment of recurrent glioblastoma, and CDX-011, an antibody-drug conjugate for which we initiated an accelerated approval study in December 2013 for
the treatment of advanced breast cancer. We also have a number of earlier stage candidates in clinical development, including CDX-1127, a therapeutic fully human monoclonal antibody in a
Phase&nbsp;1 study for cancer indications, CDX-1135, a molecule that inhibits a part of the immune system called the complement system, CDX-301, an immune cell mobilizing agent and dendritic cell
growth factor and CDX-1401, an APC Targeting Technology&#153; program in a Phase&nbsp;1 study for cancer indications. Our drug candidates address market opportunities for which we believe
current therapies are inadequate or non-existent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are building a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Our program assets provide us with the strategic
options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach allows us to maximize the overall
value of our technology and product portfolio while best ensuring the expeditious development of each individual product. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Rindopepimut (CDX-110)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Rindopepimut is an experimental immunotherapeutic drug that targets the tumor-specific molecule, epidermal growth factor receptor variant III, or
EGFRvIII. EGFRvIII is a mutated form of the epidermal growth factor receptor, or EGFR, that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell
growth. EGFRvIII is expressed in approximately 30% of glioblastoma, or GB, tumors, the most common and aggressive form of brain cancer. The rindopepimut vaccine is composed of the EGFRvIII peptide
linked to a carrier protein called Keyhole Limpet Hemocyanin, or KLH, and administered together with the adjuvant GM-CSF. The Food and Drug Administration, or FDA, and the European Medicines Agency,
or EMA, have both granted orphan drug designation for rindopepimut for the treatment of EGFRvIII expressing GB and the FDA has also granted Fast Track designation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Glembatumumab Vedotin (CDX-011)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>CDX-011 is an antibody-drug conjugate, or ADC, for the treatment of patients with glycoprotein NMB, or&nbsp;gpNMB, expressing advanced, refractory
breast cancer. CDX-011 consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E, or MMAE. CDX-011 targets the protein&nbsp;gpNMB, which is
over-expressed in a variety of cancers, including breast cancer and melanoma. The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle
Genetics,&nbsp;Inc. The FDA has granted Fast Track designation to CDX-011 for the treatment of advanced, refractory/resistant&nbsp;gpNMB-expressing breast cancer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with our acquisition of CuraGen Corporation, we assumed the license agreement between CuraGen and Seattle Genetics, whereby CuraGen acquired the rights to proprietary ADC technology,
with the right to sublicense, for use with its proprietary antibodies for the potential treatment of cancer. Under the terms of the agreement, we have the responsibility of using commercially
reasonable efforts to develop, commercialize and market such treatment. In furtherance of these responsibilities, technical assistance from Seattle Genetics is available to us as necessary. We may be
required to pay milestones of up to $7.5&nbsp;million upon obtaining first approval for commercial sale in a first indication and royalty payments in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=631031,FOLIO='2',FILE='DISK121:[14ZCX2.14ZCX45802]DA45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<A NAME="page_da45802_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
mid-single digits on any net product sales to Seattle Genetics with respect to development and commercialization of the ADC technology, including our CDX-011 program. The term of the agreement
varies country to country and may be until the later of the expiration of the last relevant patent or the 10<SUP>th</SUP>&nbsp;anniversary of the first commercial sale. The agreement allows us to
terminate with prior written notice, with both parties being able to terminate the agreement for an uncured material breach or insolvency of the other party. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
patent rights licensed from Seattle Genetics include issued patents and pending applications in Australia, Canada, Europe, the U.S. and Japan which include composition of matter claims relating to
the toxin and conjugation technology. If maintained to full term in due course, the main Seattle Genetics patent rights would have estimated patent expiry dates ranging from 2023 in Europe to 2026 in
the U.S. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> CDX-1127  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>CDX-1127 is a human monoclonal antibody that targets CD27, a potentially important target for immunotherapy of various cancers. CD27 acts downstream
from CD40 and may provide a novel way to regulate the immune responses. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. CDX-1127 is an agonist
antibody designed to have two potential therapeutic mechanisms. CDX-1127 has been shown to activate immune cells that can target and eliminate cancerous cells in tumor-bearing mice and to directly
kill or inhibit the growth of CD27-expressing lymphomas and leukemias in vitro and in vivo. Both mechanisms have been seen even at low doses in preclinical models. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> CDX-1135  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>CDX-1135 is a molecule that inhibits a part of the human immune system called the complement system. The complement system is a series of proteins
that are important initiators of the body's acute inflammatory response against disease, infection and injury. Excessive complement activation also plays a role in some persistent inflammatory
conditions. CDX-1135 is a soluble form of naturally occurring Complement Receptor 1 that has been shown to inhibit the activation of the complement cascade in animal models and in human clinical
trials. In preclinical studies, CDX-1135 has been shown to inhibit both the classical and alternative pathways of complement activation. Our initial experience under an investigator sponsored IND
indicated that CDX-1135 limits complement abnormalities in Dense Deposit Disease, or DDD, which is a rare and devastating disease that is caused by uncontrolled activation of the alternative pathway
of complement activation and leads to progressive kidney damage in children. There is currently no treatment for patients with DDD and about half progress to end-stage renal disease within
10&nbsp;years. Because DDD recurs in virtually all patients who receive a kidney transplant, transplantation is not a viable option for these patients. In animal models of DDD, CDX-1135 treatment
showed evidence of reversal of kidney damage. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> Other Clinical and Pre-Clinical Programs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have several other programs in clinical and pre-clinical development. The status of each of the other programs that we currently believe is
significant to our business is summarized in the table below: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="97pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="139pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:66pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Product Candidate

<!-- COMMAND=ADD_SCROPPEDRULE,66pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Indication/Field </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stage of Clinical Development </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Cancer,&nbsp;autoimmune&nbsp;disease&nbsp;and&nbsp;transplant</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2><B> Corporate Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a Delaware corporation organized in 1983. On October&nbsp;1, 2009, a wholly-owned subsidiary of Celldex merged with and into CuraGen
Corporation. On December&nbsp;31, 2009, CuraGen Corporation was merged with and into Celldex and the separate existence of CuraGen ceased. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
principal executive offices are located at 119 Fourth Avenue, Needham, Massachusetts 02494 and our telephone number is (781)&nbsp;433-0771. Our corporate website is www.celldextherapeutics.com.
The information on our website is not incorporated by reference into this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=507653,FOLIO='3',FILE='DISK121:[14ZCX2.14ZCX45802]DA45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc45802_1_4"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2>
<A HREF="#bg45802a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc45802_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dc45802_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements
about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made
through the use of words or phrases such as "anticipate," "estimate," "plans," "projects," "continuing," "ongoing," "expects," "management believes," "we believe," "we intend" and similar words or
phrases. Accordingly, these statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking
statements are qualified in their entirety by reference to the risk factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Forward-looking
statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management's expectations and assumptions at the time the statements are
made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the
forward-looking statements for many reasons including the factors described in the section entitled "Risk Factors" in this prospectus and in any risk factors described in a supplement to this
prospectus or in other filings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. We undertake no obligation to publicly revise any
forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks
we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in this
prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=549936,FOLIO='4',FILE='DISK121:[14ZCX2.14ZCX45802]DC45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<A NAME="page_dc45802_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc45802_risk_factors"> </A>
<A NAME="toc_dc45802_2"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the
risks and other information we include or incorporate by reference in this prospectus and any prospectus supplement. In particular, you should consider the risk factors under the heading "Risk
Factors" included in our most recent Annual Report on Form&nbsp;10-K, as may be revised or supplemented by our subsequent Quarterly Reports on Form&nbsp;10-Q or Current Reports on Form&nbsp;8-K,
each of which are on file with the SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the
future. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may
also affect our business operations. Additional risk factors may be included in a prospectus supplement relating to a particular offering of securities. Our business, financial condition or results of
operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment.
This prospectus is qualified in its entirety by these risk factors.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=913161,FOLIO='5',FILE='DISK121:[14ZCX2.14ZCX45802]DC45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<A NAME="page_dc45802_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc45802_ratios_of_combined_fixed_charg__rat02955"> </A>
<A NAME="toc_dc45802_3"> </A>
<BR></FONT><FONT SIZE=2><B>  RATIOS OF COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth our consolidated ratios of earnings to combined fixed charges and preferred stock dividends for the nine months ended
September&nbsp;30, 2013 and the years ended December&nbsp;31, 2012, 2011, 2010, 2009 and 2008. We do not have any outstanding shares of preferred stock and therefore have not paid any preferred
stock dividends. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Ratios of Combined Fixed Charges  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="100pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TH COLSPAN=19 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TH>
<TH style="font-family:arial;">&nbsp;</TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine Months Ended<BR>
September&nbsp;30, 2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2012 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2011 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2010 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2009 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2008 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=19 VALIGN="BOTTOM" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Due
to our losses from continuing operations for the nine months ended September&nbsp;30, 2013 and the years ended December&nbsp;31, 2012,
2011, 2010, 2009 and 2008, earnings were insufficient to cover fixed charges by $59.3 million, $58.1&nbsp;million, $43.4&nbsp;million, $6.5&nbsp;million, $36.9&nbsp;million and
$48.8&nbsp;million, respectively. For this reason, no ratios are provided. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=834661,FOLIO='6',FILE='DISK121:[14ZCX2.14ZCX45802]DC45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<A NAME="page_dc45802_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><A
NAME="dc45802_use_of_proceeds"> </A>
<A NAME="toc_dc45802_4"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless otherwise provided in the applicable prospectus supplement to this prospectus used to offer specific securities, we expect to use the net
proceeds from any offering of securities by us for general corporate purposes, which may include acquisitions, capital expenditures, investments, and the repayment, redemption or refinancing of all or
a portion of any indebtedness or other securities outstanding at a particular time, to fund our operations until we receive FDA approval of our products and are able to commercialize our products and
to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities in anticipation of FDA approval of our products. Pending the application of the
net proceeds, we expect to invest the net proceeds in short-term, interest-bearing instruments with a maturity of three months or less at the date of purchase that consist primarily of investments in
money market mutual funds with commercial banks and financial institutions or other investment-grade securities. Such investments may include depositing such net proceeds into, and maintaining cash
balances with, financial institutions in excess of insured limits. We will not receive any of the proceeds from the sale of our securities by any selling securityholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc45802_selling_securityholders"> </A>
<A NAME="toc_dc45802_5"> </A>
<BR></FONT><FONT SIZE=2><B>  SELLING SECURITYHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information about selling securityholders, if any, will be set forth in a prospectus supplement, in an amendment to the registration statement of
which this prospectus is a part, or in other filings we make with the SEC under the Exchange Act, which are incorporated by reference. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=349827,FOLIO='7',FILE='DISK121:[14ZCX2.14ZCX45802]DC45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<A NAME="page_dc45802_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc45802_descriptions_of_securities_we_may_offer"> </A>
<A NAME="toc_dc45802_6"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTIONS OF SECURITIES WE MAY OFFER    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus contains summary descriptions of the common stock, preferred stock, warrants, depositary shares and units that we or any selling
securityholders may offer and sell from time to time. The preferred stock may also be exchangeable for and/or convertible into shares of common stock or another series of preferred stock. When one or
more of these securities are offered in the future, a prospectus supplement will explain the particular terms of the securities and the extent to which these general provisions may apply. These
summary descriptions and any summary descriptions in the applicable prospectus supplement do not purport to be complete descriptions of the terms and conditions of each security and are qualified in
their entirety by reference to our third restated certificate of incorporation, as amended, our by-laws and by applicable Delaware law and any other documents referenced in such summary descriptions
and from which such summary descriptions are derived. If any particular terms of a security described in the applicable prospectus supplement differ from any of the terms described herein, then the
terms described herein will be deemed superseded by the terms set forth in that prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may issue securities in book-entry form through one or more depositaries, such as The Depository Trust Company, Euroclear or Clearstream, named in the applicable prospectus supplement. Each sale of
a security in book-entry form will settle in immediately available funds through the applicable depositary, unless otherwise stated. We will issue the securities only in registered form, without
coupons, although we may issue the securities in bearer form if so specified in the applicable prospectus supplement. If any securities are to be listed or quoted on a securities exchange or quotation
system, the applicable prospectus supplement will say so. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=111738,FOLIO='8',FILE='DISK121:[14ZCX2.14ZCX45802]DC45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<A NAME="page_dc45802_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dc45802_description_of_common_stock"> </A>
<A NAME="toc_dc45802_7"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of September&nbsp;30, 2013, we are authorized to issue up to 297,000,000 shares of common stock, par value $.001 per share. As of
September&nbsp;30, 2013, approximately 81,108,109 shares of common stock were outstanding. All outstanding shares of our common stock are fully paid and non-assessable. Our common stock is listed on
the NASDAQ Global Market under the symbol "CLDX". </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Dividends  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The board of directors may, out of funds legally available, at any regular or special meeting, declare dividends to the holders of shares of our
common stock as and when it deems expedient, subject to the rights of holders of the preferred stock, if any. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Voting  </I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Each share of common stock entitles the holders to one vote per share on all matters requiring a vote of the stockholders, including the election of
directors. No holders of shares of common stock shall have the right to vote such shares cumulatively in any election for the board of directors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Rights Upon Liquidation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders of our common stock will be entitled to share
equally in our assets available for distribution after payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in full. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Miscellaneous  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No holders of shares of our common stock shall have any preemptive rights to subscribe for, purchase or receive any shares of any class, whether now
or hereafter authorized, or any options or warrants to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be issued, sold or offered
for sale by Celldex. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Anti-Takeover Provisions  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain provisions in our third restated certificate of incorporation, as amended, and applicable Delaware corporate law, as well as our shareholder
rights agreement, may have the effect of discouraging a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders receiving a
substantial premium over the current market price of our shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of
our corporation. These provisions may also tend to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to elect even a single
director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to our shareholder rights agreement (referred to in this prospectus as the rights agreement) a dividend of one Preferred Stock Purchase Right (referred to in this prospectus as a right) for
each share of common stock of Celldex was declared for each outstanding share of common stock of Celldex on November&nbsp;11, 2004. Each share of common stock of Celldex issued after such date is
also issued with a right. Each right entitles the registered holder to purchase from Celldex a unit consisting of one one-ten thousandth of a share of Celldex Series&nbsp;C-1&nbsp;Junior
Participating Cumulative Preferred Stock, at a cash exercise price of $35 per unit, subject to adjustment as specified in the rights agreement. We describe the rights more completely in the rights
agreement itself, which is contained in Exhibit&nbsp;4.1 to our Registration Statement on Form&nbsp;8-A filed on November&nbsp;8, 2004. The summary of the provisions of the rights agreement is
qualified in its entirety by reference to that agreement. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Computershare
Trust Company, N.A. is presently the transfer agent and registrar for our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=27,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=563070,FOLIO='9',FILE='DISK121:[14ZCX2.14ZCX45802]DC45802A.;3',USER='HYUNG',CD=';4-NOV-2014;09:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de45802_1_10"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2>
<A HREF="#bg45802a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_description_of_preferred_stock"> </A>
<A NAME="toc_de45802_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF PREFERRED STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At September&nbsp;30, 2013, the Company had authorized preferred stock comprised of 3,000,000 shares of Class&nbsp;C Preferred Stock of which
350,000 shares has been designated as Class&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock, the terms of which are to be determined by our board of directors. As of
September&nbsp;30, 2013, there was no preferred stock outstanding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Class&nbsp;C Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This section describes the general terms and provisions of our Class&nbsp;C Preferred Stock. The applicable prospectus supplement will describe the
specific terms of the shares of preferred stock offered through that prospectus supplement, as well as any general terms described in this section that will not apply to those shares of preferred
stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors has been authorized to provide for the issuance of the 2,650,000 unissued and undesignated shares of our Class&nbsp;C Preferred Stock. In general, our third restated
certificate of incorporation, as amended, authorizes our board of directors to issue new shares of our common stock or preferred stock without further stockholder action, provided that there are
sufficient authorized shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>With
respect to each series of our Class&nbsp;C Preferred Stock, our board of directors has the authority to fix the following terms:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the designation of the series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the number of shares within the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether dividends are cumulative and, if cumulative, the dates from which
dividends are cumulative; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the rate of any dividends, any conditions upon which dividends are payable,
and the dates of payment of dividends; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether interests in the shares of preferred stock will be represented by
depositary shares as more fully described below under "Description of Depositary Shares"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether the shares are redeemable, the redemption price and the terms of
redemption; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the amount payable to you for each share you own if we dissolve or
liquidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether the shares are convertible or exchangeable, the price or rate of
conversion or exchange, and the applicable terms and conditions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any restrictions on issuance of shares in the same series or any other
series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>voting rights applicable to the series of preferred stock;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any other rights, priorities, preferences, restrictions or limitations of
such series. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
rights with respect to any shares of our Class&nbsp;C Preferred Stock will be subordinate to the rights of our general creditors. Shares of our Class&nbsp;C Preferred Stock that we issue in
accordance with their terms will be fully paid and nonassessable, and will not be entitled to preemptive rights unless specified in the applicable prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to issue preferred stock, or rights to purchase such shares, could discourage an unsolicited acquisition proposal. For example, we could impede a business combination by issuing a series
of preferred stock containing class voting rights that would enable the holders of such preferred stock to block a business combination transaction. Alternatively, we could facilitate a business
combination transaction by issuing a series of preferred stock having sufficient voting rights to provide a required percentage vote of the stockholders. Additionally, under certain circumstances, our
issuance of preferred stock could adversely affect the voting power of the holders of our common stock. Although our board of directors is required to make any determination to issue any preferred
stock based on its judgment as to the best interests of our stockholders, our board of directors could act in a manner that would discourage an acquisition attempt or other transaction that some, or a
majority, of our stockholders might believe to be in their best interests or </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=28,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=509481,FOLIO='10',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>in
which stockholders might receive a premium for their stock over prevailing market prices of such stock. Our board of directors does not at present intend to seek stockholder approval prior to any
issuance of currently authorized stock, unless otherwise required by law or applicable stock exchange requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Terms of the Preferred Stock That We May Offer and Sell to You  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We summarize below some of the provisions that will apply to the preferred stock that we may offer to you unless the applicable prospectus supplement
provides otherwise. This summary may not contain all information that is important to you. You should read the prospectus supplement, which will contain additional information and which may update or
change some of the information below. Prior to the issuance of a new series of preferred stock, we will further amend our third restated certificate of incorporation, as amended, designating the stock
of that series and the terms of that series. We will file&nbsp;a copy of the certificate of designation that contains the terms of each new series of preferred stock with the SEC each time we issue
a new series of preferred stock. Each certificate of designation will establish the number of shares included in a designated series and fix the designation, powers, privileges, preferences and rights
of the shares of each series as well as any applicable qualifications, limitations or restrictions. You should refer to the applicable certificate of designation as well as our third restated
certificate of incorporation, as amended, before deciding to buy shares of our preferred stock as described in the applicable prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors has the authority, without further action by the stockholders, to issue preferred stock in one or more series and to fix the number of shares, dividend rights, conversion
rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any other rights, preferences, privileges and restrictions applicable to each such series of preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
issuance of any preferred stock could adversely affect the rights of the holders of common stock and, therefore, reduce the value of the common stock. The ability of our board of directors to
issue preferred stock could discourage, delay or prevent a takeover or other corporate action. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
terms of any particular series of preferred stock will be described in the prospectus supplement relating to that particular series of preferred stock, including, where
applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the designation, stated value and liquidation preference of such preferred
stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the number of shares within the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the offering price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the dividend rate or rates (or method of calculation), the date or dates
from which dividends shall accrue, and whether such dividends shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether interests in the shares of preferred stock will be represented by
depositary shares as more fully described below under "Description of Depositary Shares"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any redemption or sinking fund provisions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the amount that shares of such series shall be entitled to receive in the
event of our liquidation, dissolution or winding-up; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the terms and conditions, if any, on which shares of such series shall be
convertible or exchangeable for shares of our stock of any other class or classes, or other series of the same class; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the voting rights, if any, of shares of such series; the status as to
reissuance or sale of shares of such series redeemed, purchased or otherwise reacquired, or surrendered to us on conversion or exchange; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the conditions and restrictions, if any, on the payment of dividends or on
the making of other distributions on, or the purchase, redemption or other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior to the shares of
such series as to dividends or upon liquidation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=29,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1033975,FOLIO='11',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the conditions and restrictions, if any, on the creation of indebtedness by
us or by any subsidiary, or on the issuance of any additional stock ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any additional dividend, liquidation, redemption, sinking or retirement fund
and other rights, preferences, privileges, limitations and restrictions of such preferred stock. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
description of the terms of a particular series of preferred stock in the applicable prospectus supplement will not be complete. You should refer to the applicable amendment to our third restated
certificate of incorporation, as amended, for complete information regarding a series of preferred stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
preferred stock will, when issued against payment of the consideration payable therefor, be fully paid and nonassessable. Unless otherwise specified in the applicable prospectus supplement, each
series of preferred stock will, upon issuance, rank senior to the common stock and on a parity in all respects with each other outstanding series of preferred stock. The rights of the holders of our
preferred stock will be subordinate to that of our general creditors. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=30,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=19453,FOLIO='12',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_description_of_warrants"> </A>
<A NAME="toc_de45802_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF WARRANTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We summarize below some of the provisions that will apply to the warrants unless the applicable prospectus supplement provides otherwise. This summary
may not contain all information that is important to you. The complete terms of the warrants will be contained in the applicable warrant certificate and warrant agreement. These documents have been or
will be included in or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the warrant certificate and the warrant agreement. You
should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> General  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may issue, together with other securities or separately, warrants to purchase common stock, preferred stock or other securities. We may issue the
warrants under warrant agreements to be entered into between us and a bank or trust company, as warrant agent, all as set forth in the applicable prospectus supplement. The warrant agent would act
solely as our agent in connection with the warrants of the series being offered and would not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of
warrants. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
applicable prospectus supplement will describe the following terms, where applicable, of warrants in respect of which this prospectus is being
delivered:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the title of the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the designation, amount and terms of the securities for which the warrants
are exercisable and the procedures and conditions relating to the exercise of such warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the designation and terms of the other securities, if any, with which the
warrants are to be issued and the number of warrants issued with each such security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the price or prices at which the warrants will be issued; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the aggregate number of warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any provisions for adjustment of the number or amount of securities
receivable upon exercise of the warrants or the exercise price of the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the price or prices at which the securities purchasable upon exercise of the
warrants may be purchased; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>if applicable, the date on and after which the warrants and the securities
purchasable upon exercise of the warrants will be separately transferable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>if applicable, a discussion of the material U.S. federal income tax
considerations applicable to the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any other terms of the warrants, including terms, procedures and limitations
relating to the exchange and exercise of the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the date on which the right to exercise the warrants shall commence and the
date on which the right shall expire; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>if applicable, the maximum or minimum number of warrants which may be
exercised at any time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the identity of the warrant agent; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any mandatory or optional redemption provision; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether the warrants are to be issued in registered or bearer form; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether the warrants are extendible and the period or periods of such
extendibility; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>information with respect to book-entry procedures, if any;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any other terms of the warrants. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=31,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=708346,FOLIO='13',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends, if any, or
payments upon our liquidation, dissolution or winding-up or to exercise voting rights, if any. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> Exercise of Warrants  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each warrant will entitle the holder thereof to purchase such number of shares of common stock or preferred stock or other securities at the exercise
price as will in each case be set forth in, or be determinable as set forth in, the applicable prospectus supplement. Warrants may be exercised at any time up to the close of business on the
expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be exercised as set forth in
the applicable prospectus supplement relating to the warrants offered thereby. Upon receipt of payment and proper completion and due execution at the corporate trust office of the warrant agent or any
other office indicated in the applicable prospectus supplement of the warrant certificate, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants
represented by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Enforceability of Rights of Holders of Warrants  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or
trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any
default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a
warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon
exercise of, that holder's warrant(s). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Modification of the Warrant Agreement  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The warrant agreement will permit us and the warrant agent, without the consent of the warrant holders, to supplement or amend the agreement in the
following circumstances:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>to cure any ambiguity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>to correct or supplement any provision which may be defective or
inconsistent with any other provisions; or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>to add new provisions regarding matters or questions that we and the warrant
agent may deem necessary or desirable and which do not adversely affect the interests of the warrant holders. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=32,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=978584,FOLIO='14',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_description_of_depositary_shares"> </A>
<A NAME="toc_de45802_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF DEPOSITARY SHARES    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We summarize below some of the provisions that will apply to depositary shares unless the applicable prospectus supplement provides otherwise. This
summary may not contain all information that is important to you. The complete terms of the depositary shares will be contained in the depositary agreement and depositary receipt applicable to any
depositary shares. These documents have been or will be included in or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the
depositary agreement and the depositary receipt. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> General  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may, at our option, elect to offer fractional or multiple shares of common stock or preferred stock, rather than single shares of common stock or
preferred stock (to be set forth in the prospectus supplement relating to such depositary shares). In the event we elect to do so, depositary receipts evidencing depositary shares will be issued to
the public. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
shares of common stock or any class or series of preferred stock represented by depositary shares will be deposited under a deposit agreement among us, a depositary selected by us, and the holders
of the depositary receipts. The depositary will be a bank or trust company having its principal office in the United States and
having a combined capital and surplus of at least $50,000,000. Subject to the terms of the deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable
fraction of a share of common stock or preferred stock represented by such depositary share, to all the rights and preferences of the shares of common stock or preferred stock represented by the
depositary share, including dividend, voting, redemption and liquidation rights. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the fractional shares of
common stock or the related class or series of preferred shares in accordance with the terms of the offering described in the related prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=33,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=853341,FOLIO='15',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_description_of_units"> </A>
<A NAME="toc_de45802_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF UNITS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued so that
the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit
agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The
applicable prospectus supplement may describe:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the designation and terms of the units and of the securities comprising the
units, including whether and under what circumstances those securities may be held or transferred separately; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any provisions for the issuance, payment, settlement, transfer or exchange
of the units or of the securities comprising the units; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the terms of the unit agreement governing the units; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>United States federal income tax considerations relevant to the units;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>whether the units will be issued in fully registered global form. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their entirety by
reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. The forms of the unit agreements and other
documents relating to a particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to you. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=34,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=862682,FOLIO='16',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_plan_of_distribution"> </A>
<A NAME="toc_de45802_5"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated
transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities, including
without limitation, warrants and subscriptions. We or any selling securityholders may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers.
We or any selling securityholders may distribute securities from time to time in one or more transactions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>at a fixed price or prices, which may be changed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>at market prices prevailing at the time of sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>at prices related to such prevailing market prices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>at varying prices determined at the time of sale; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>at negotiated prices. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>A prospectus supplement or supplements will describe the terms of the
offering of the securities, including:</FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the name or names of the underwriters, dealers, agents or selling
securityholders participating in the offering, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>the purchase price of the securities sold by us to any underwriter or dealer
and the net proceeds we expect to receive from the offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any over-allotment options under which underwriters may purchase additional
securities from us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any agency fees or underwriting discounts or commissions and other items
constituting agents' or underwriters' compensation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any public offering price; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any discounts or concessions allowed or reallowed or paid to dealers;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>any securities exchange or market on which the securities may be listed. </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Only
underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering
price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting
agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the
underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any
discounts or commissions or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the
prospectus supplement, naming the underwriter, the nature of any such relationship. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
or any selling securityholders may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will
describe any commissions and other compensation we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for
the period of its appointment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
or any selling securityholders may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set
forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=35,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=895697,FOLIO='17',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments
that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents or underwriters may make a market in these securities, but will
not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is currently no market
for any of the offered securities, other than our common stock which is listed on the NASDAQ Global Market. We have no current plans for listing of the preferred stock, warrants or subscription rights
on any securities exchange or quotation system; any such listing with respect to any particular preferred stock, warrants or subscription rights will be described in the applicable prospectus
supplement or other offering materials, as the case may be. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation&nbsp;M under the Exchange Act. Overallotment
involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a
specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters
to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or short covering transaction to cover short positions. Those activities
may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
agents and underwriters who are qualified market makers on the NASDAQ Global Market may engage in passive market making transactions in the securities on the NASDAQ Global Market in accordance
with Regulation&nbsp;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable
volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such
security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be lowered when certain purchase limits are exceeded. Passive
market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=36,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=532509,FOLIO='18',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_legal_matters"> </A>
<A NAME="toc_de45802_6"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us by
Lowenstein Sandler LLP, Roseland, New Jersey. If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus are passed upon by counsel for the
underwriters, dealers, agents or selling securityholders, if any, such counsel will be named in the prospectus supplement relating to such offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_experts"> </A>
<A NAME="toc_de45802_7"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The financial statements and management's assessment of the effectiveness of internal control over financial reporting (which is included in
Management's Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2012 have
been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_where_you_can_find_more_information"> </A>
<A NAME="toc_de45802_8"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act of which this prospectus
forms&nbsp;a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of certain agreements or documents that are
exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is qualified in all
respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at
http://www.sec.gov. The SEC's website contains reports, proxy statements and other information regarding issuers, such as Celldex Therapeutics,&nbsp;Inc., that file electronically with the SEC. You
may also read and copy any document we file with the SEC at the SEC's Public Reference Room, located at 100&nbsp;F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the operation of its Public Reference Room. We make available free of charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q,
Current Reports on Form&nbsp;8-K, Proxy Statements on Schedule&nbsp;14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or
furnished to the SEC. Our website address is http://www.celldextherapeutics.com. Please note that our website address is provided as an inactive textual reference only. Information contained on or
accessible through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference unless such information is otherwise specifically referenced
elsewhere in this prospectus or the prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=37,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=648754,FOLIO='19',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<A NAME="page_de45802_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A
HREF="#bg45802a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="de45802_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_de45802_9"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The SEC allows us to incorporate by reference in this prospectus much of the information we file with the SEC, which means that we can disclose
important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus.
Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or
incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document
previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No.&nbsp;000-15006) and any future filings we make
with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those
documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Our Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2012, filed with the SEC on March&nbsp;8, 2013 (including the portions of our Proxy Statement on Schedule&nbsp;14A, filed with the SEC on April&nbsp;23, 2013, incorporated by
reference therein); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended
March&nbsp;31, 2013, June&nbsp;30, 2013 and September&nbsp;30, 2013, filed on May&nbsp;3, 2013, August&nbsp;6, 2013 and November&nbsp;8, 2013, respectively; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>Our Current Reports on Form&nbsp;8-K filed with the SEC on
February&nbsp;4, 2013, February&nbsp;6, 2013, March&nbsp;7, 2013 (with respect to Item&nbsp;8.01 only), May&nbsp;20, 2013 and June&nbsp;13, 2013; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>The description of our Common Stock contained in our registration statement
on Form&nbsp;8-A, filed with the SEC on September&nbsp;22, 1986 under Section&nbsp;12 of the Securities Exchange Act, and any amendments or reports filed for the purpose of updating such
description; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=3>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>The description of the rights to purchase our
Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock contained in our registration statement on Form&nbsp;S-4, filed with the SEC on December&nbsp;21, 2007, our registration
statement on Form&nbsp;8-A filed with the SEC on November&nbsp;8, 2004, our registration statement on Form&nbsp;8-A/A filed with the SEC on October&nbsp;22, 2007, our registration statement on
Form&nbsp;8-A/A filed with the SEC on March&nbsp;7, 2008, and any amendment or report filed with the SEC for the purposes of updating such descriptions. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Nothing
in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item&nbsp;2.02 or 7.01 of Form&nbsp;8-K. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by reference
other than exhibits to those documents. Requests should be addressed to: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>Celldex Therapeutics,&nbsp;Inc.</B></FONT><FONT SIZE=2><BR>
Attention: Investor Relations<BR>
119 Fourth Avenue<BR>
Needham, Massachusetts 02494<BR>
Telephone number: (781)&nbsp;433-0771 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=38,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=2829,FOLIO='20',FILE='DISK121:[14ZCX2.14ZCX45802]DE45802A.;4',USER='LPALLES',CD=';4-NOV-2014;10:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bg45801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g148431.jpg" ALT="GRAPHIC" WIDTH="261" HEIGHT="63">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Up to 76,086 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>Prospectus Supplement  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>November 6, 2014  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=39,EFW="2222060",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=714586,FOLIO='blank',FILE='DISK116:[14ZCX1.14ZCX45801]HO45801A.;14',USER='DPERRY',CD=';5-NOV-2014;13:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g148431.jpg
<DESCRIPTION>G148431.JPG
<TEXT>
begin 644 g148431.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!%35),3%]'4D%02$E#4SI;0T5,3$1%
M6%]42$5205!%551)0U-=0T5,3$1%6%]42$5205!%551)0U-?0U],3T=/+D50
M4__;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_``!$(`#\!!0,!(@`"$0$#$0'_Q``?```"`@("`P$````````````)
M"@`(!@<%"P$"!`/_Q`!($``!!`(!`@0$`P`,#`<!```$`@,%!@$'"`D1`!(3
M%`H5%B$7,4$8&B(C)#A187%XM_`9)B<R6')U@9&4H=$I,S0U-CK60O_$`!T!
M``(#``,!`0````````````4&!`<(``(#"0'_Q``T$0`"`P`"`00!`@0$!04`
M```"`P$$!081$@`'$R$4%2((,3)!%B,S420F87&S-39"=<'_V@`,`P$``A$#
M$0`_`'^/'JI248SE6<8QC&<YSG^3'WSG^C&/OG/Z8^^?MX]LY[?W_P"O]&/S
MS_-XZ^7K8=7'F5MC=^S^*T?$;-XDZ9HLB95)K5YCOTQLW9XB\YR/9]E3T(0Z
MXNHVF/\`+(5FI5&?,I,K736#965N#I"5Q[SP#@6I[@[)9.;8J5`KI_*O6[;(
MZKUO,5R:JPE#[39(H$%JB`@I'YW(`H/TI<RYAG\+RXTKR;%DFL^"K6KA/;G^
M/EXFXHE2`B/LC.9*8[^-;"B1]-J\D>LSTXN+AYD!L'DG4[%<0'7!RZ1J5B0V
MY9P2F5+0^)+,T0>8B:^4PM&6W1K#,1+Z'<^FIO"L*PFC:?B>^FMF2P"H'DD@
M3)'H_.E:=`S'8;]53>#,C(O*YOVV48P_AO$3DWTEX3D/#^%-)Z]!.,)3AM&$
MH;3_`)K:$X0VG_50G&$)_P!V,>)XU=0_AIX0BN`7]'?OVO'_`#'A9J4TR77W
M*JXTW$L>_N!8]\_?V4Q]>LZ7/?GE3GD5.CDTZ\%^Q1)?89X_[-:;Q@BG^\K6
MJ.OJ![^Y[17C?UE^G%RB.`@=?<E:C7[E(J;9%H^V&9'4EG++><PVR#%LWL:'
MB)\UY><(:%KLS+O+6I*$HRI6,9*%A6%8[XSW_P"F?YOMG[_?\\?RX^_Y>.FH
M5C"DY0O"5HS^:%IPM"O]9"L92K_?C/ADWHA]6KF9K;>VKN)TC%;'Y9:=V#+`
MU2&UZDOY_L;5`BWFL%6ZB6>?(1Z-(JD?ZDA:*I<)X&FQD&.Z9#S%3)9].4K[
MGO\`#I&1G7-GBFNRRB@AUNUF[+*RG172$L:=;1`:U8B6$&7PV4HB0&>K),\0
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M@$<`(RT*$"*TT,(,TVPPVAM"4XO._./[34<NA&%E[W/M'/K:NI;WJWY^?QM-
MR/EJ9U+-.12S1!<0RQ9=W*CZD/E2X5JJ:G&G[BV]&W.M?R.'TKCL[/K93?Q+
MFVRM,#9NVKH^3!I$SL$H`8@QB?+P8!&:8\E\/7U4Y?YC9)7J+5.1NYLDJ2>R
M5=N0#S4B4OR/N2!EF6`DML]1:?LG$`0E7E0^HI&<Y:1@5XW'\09TB"!KSO"P
MN\H>.<+("HL%@L,@QNG6Z0?5'CVVY:]MPU?W5JC).2&!(J8L+8E<Q)O#I<'F
M'E*!)>'\<;,0\58(J3@IR,CYF&FHXV)EXB6#'D8N5BI(9T.0C),`MMT4Z./$
M>>%-"):<')'=<9>;4A><9$H]W]2TP$<GX]Q7DN24P#J+\*A1<"2Z$_P+M%*6
MT['A'2W^#I`H@O&9B)B>SVSSJP&[`V-_#T8CR7;3J6;*S8,R0_F5K)F%E4E_
M6OR7Y#,QWU,Q(^.F[U*](=2341=[UNV74+[4'@(K:^HK`:(79:'-'#>N*0P6
M,EAJR4V:4V7],V\0,-B3R$<"?'Q$Y'2,4*1GPFQQLX,\G^F_UR7">/6B=PS/
M"/9<XY4).XP-5FY?7L!J?;4`FP"P,W9,NOM,CZ7V:'&,HD)$ATT.$A6'2W'/
MF9*B7$9R>A:Q"2EDLTO%UZOP4:9,3LY-R`D3#0L3'#K+D926E#WAP8Z-CQ6G
M233C"&111VG'WW6VD*5A=Y]AX>3LU6\6N1=PMS-I[&8F7A9N9XW8+SRKW@;#
M&W4:,CX-F7?&:H83&P9D<X?K:VCEO7OU_P`;7R;MG,OMA1)K7"J^/CH5O*("
M46`*"\@Z7YBR0$%R`QRWB>%9.2_Q-6NHO83^H^#/'FV\JK,LYV*C+@81.UVL
M6*2%+6T_]!4NN5NR['O48XRWYAI90-5&*]5LH%LZ/4R21J"0ZWO65HT<U>=D
M])J5`UPA!1IAR-8\DZZ\/'#O)QEXR:)$LJ(AMEM6,++E:RRP1W]TTVV.E6,$
MJ_M#SER*[WY]+,*V,'4J;&SDY=ZR)1V/A2NW%60(NIB`<M1Q,3W$1$S$)WN1
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MV^K3R!W#L#<EC@.035>A)O84^_8)**@\ZNHDIF)!)(2E;`&9(\T[(Z>Z?<E/
M._YSBN]5.FGRZY1;,ZZ/,K1.PM_;3N>F:9)\O6JGK"Q6@F0I==:J&Z*S"U5N
M(AG$89$37H@HB-B?(K.1`WG&4YRE>>^P?A1OXH')'^LTS_8_KGQ33I-__8HY
MX?[7YP?V]U'Q=>IEY@<A]_%AG417GX(LH+&I7@*+);2B64PA?C6/HBCR3`%^
MZ?O[]55GZ.@6/[/&5VT1WM0AN%+V25H?!D^-@I+MP]__`!.2C^W741Z=K\3Q
MJ+>N^-2\:M76O<V[KO#:^UQ2X]<A.V*:>4EM'VRD6.C@V$/2$U.RI'D!A("(
M%-F)F0=9!C0B2'$H\*^7_P")>V7M>_2&ONGWP2OV\70EO*$F+:S<)FQR@N6'
MDCR.=5:D@Y^2@HY9#2GQW)VYL%F"-K9>$BRU*0/2?&^#\GY8%AV+F$ZG4GJW
MHV7UJ&;6+J)\&WKK45_DB"$I2##;`D)2N!F)]6MN<LP>.DE6I>%5JS'=>DE3
MK=UXQ,QY!5JK:V`[@HAAB"YD2&#[B8AN#PLY\2WR:Y#<9])<9YOCWNC8NF)B
MS[5OD389/7=B(KIDS&`ZX?D`@9%X=*E$BBGXP8PTKMALC&'<?NL)SBN[/Q`/
M4-T$>U.\W.EU<J1J];S#!MHKE<V]K9Z);>;'>60W)[*A[)295]ME]+B`#K%6
M$N+6D5R2&=;>4BN_Q"','0_.'@UPUWCQ[MZ;143=X;*AYF/,%7%VJDV@74N"
M9"H7>`=6Z_`V,%DH8G(JGB0Y&.*"F84^3A3PI`BS>!>W6YB\^XDW>RJ5[$NW
M[%?\RM8S]S':W]-ML&N]M1MJNMO[?-:K4+(Y"25!>$S"-RSFV1J\1Y&O)OV*
MNK6I*=%:PBUFZ`!%VL,N2NPM+&+CR\28B3@.^CD>XB6\>)EAG;;Q8XU6JT2Y
M\_9;+H#35@L,[*/Y)DYJ<FM;UJ2EI:1)5C"B#I*0*(,+?5C&72'W',XQE7;Q
M8+Q67A7]N'/$_O\`Z-.A_P"RJI^!?]1/KX\7."UPEM-U>!F>1F^X%]`5FI%,
MF0(&I4.1=;0IN'O.P2Q9=@6RYR^/ZE3K,'9IP%2LC3K<$4X.R]5E3CFSR3D%
MW*X_F/T+<V[A17K``@E(6"&6.:<KKU:X20!\KF*2)$`>4$0Q+X_<S,/$IZ.S
M?53K_BU8ESR(C:TT!/@I80;GN/\`<7QJ!C)B"+QZB9@[7B>%`X[K=]9F]Q>;
MKK/I-2DA076AB0Y!>K^2ED46*42XAD@&5&&K.)9AYKR-X?C(`AII25%N*R,\
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MPA9J)%O@Y#;0=7FG1XJ%3%-3Z5X^FK`ETV&F7GXQ#+R!IB/,=JBW?J46(5<;
M^.=ELI3\@,@";$Q'QDR`E:SF9^A883/4]=]3T:V>5\?X_8RJNSHAGLV[,5,Q
MCT6OQ+%HI"!05X$'2KM/S&5A:L)ED=R'E`E,&+\3Q,9QG[X_O_VSC]<?GC/@
M>O4;ZCFE^F]I=G9NRV2;7;[.>Y!ZLU-"2#$?9]C3HV!WI)L4T@4X>#K]?!?0
M?9+1("/`1;;@0+31LS*Q4:8:S,R_L7ZN7EU77;]UPHJU4#Y,:POY1'<P(B,1
M)L89"M2Q)C#$!(H+7[]/,IV+]^PNK3JK)MBPV>@6`_WGJ)(BF9@0`8(S.1`!
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MY091R3Y97?DGM)S=O(#<FVW%H6C86P9^QA^EDG++<6\ZV%##L8-;:+2P-#`@
M#LH)::>0VTE+C;:L>1.;<3N7.W.'FRF-@ZOE$N!'9##N]'E''55>^P(Q&'<Q
MDPPWA:@Y$=&7OD=F";S+0+[SF6?=1Y!\8=5?'?<[8XWR@M:G<?76J\;*5BM,
M?-3`)E2R`>I!]=R1B+=5@DMXFR9$O-BVXDJ>_1/Y9R:ARU`[O`-S4L)16\(8
M_'I*.*M*Y0\?&6**LE-BW7&1.;!'=IFNQ+5V@><JN)V\N&&X[%H_?U-*JEQ@
MEJ?!-:P055KI7UNJ:C[E0[`Z*(Q9:I*^7/MI!EIDL$I+\/.@1,Z$?%C5P\=F
M;?=?\)>NAQ1<B)T7`=I@6<K!DV$12-S\;MAR0R59<"(<;<:+AY=0"$DC*]>F
M;'@1L)?0S("-KA$EA.D#R))ZDKO3;?G:B'=V5/V1S9ZDF/4S\(6X7ZG9V:Q%
M)<1+D.$P2V1FZ=A])S=N<56WY9L-A^?1]/\`VQ][\#FV%8M:EBMF:>3FLTM.
M1DIHV<^L(P_3HS'F?QB1##Z<P5A#2A80X9@HG<H]O6TVY>CQ2Q'(>.<B>E6)
M=JF#3^:U,PFG8(?$?DF1,8;,`/:V"\4-`UQ3/B9Q%WKS7W)!:/X_T]ZU6V52
M@^7D'W%!5>CU=LM@22NEYG<MN,P59BE$(2Z]ELB1E#%,P]?CI:;+$CWNP2XH
M\0N&W0YXRS=WME@"FMDSD8,+LG<!\:,UL';%@:R[(1NN];UITXA^,K[17?,#
M2XPY3?E'5:+K*E$"ES(63U*H\)^AAQ0%KE:`?,GI]W+SRUJCBMQ<AMBB@H0[
M*3!N4MMAPT9A3:5+0VQ3==PCZ!8T-P\UL>:5VY4<LMO<OMDE;%VK,=VV/7%J
M%*BWR\4^@PSV6_-%5L$EQ6<OE899<FYXI.9>?*;0\:XT*R#'@Y(]^?XB+/(#
M;A8DLJXP'VFC)2#[Y#,2J]L2$]@B)Z;4S1+KOQ:\C8*S08U-;CWL=0CN*N_[
MF7JO::TS\E'CJGA$PVQ(S!"4Q,3`P06K@_M5-:H;'M8]Z>O53M/+'E+LK5E^
M@HBI5JVPA%BT5!A90](0C%.PK,[6I^6QGO89Z;@2DVA\X=`P0I$++!1PN`$,
MON%LY&R4C#\?MY2\.IU,M%:=VA)1>62&Q'L2(-%GR@LM%.X4T,Y@EIK*"'4J
M;97C#BTY2G./"+/"VZGZ\Y<<;+='97Z\?NF@`/-MN9:41&V:=&J4P+E?F3C"
M28B?.95A>?)G*L>?"D_N<O[3D.!8826@)1GW$9,QI\/(L95C'K1\D*]'FM^;
MMG&,N"OO)[]L]LJ_+/Y>*1X+LOOH)M\ILMIZ(F<E$1\B3('P$Q$0'43\JQ&.
MA%<`/41$>K$]AN:[/..([:]RZRYK9VM:5^<R!$SJZ2HMUXGP`5C\#SMI2M8P
M":RZZ0`06,>DS?A(X>.=E.;E@<9PN7%K_&^''*RK/F1&GN;:DBVL([]L^N8$
M*\M?;OG+2<9SG&,=G2?"$_1-V`YTX.K5NWAEN<A57`V3(6'CV*;,$H#"5?J3
M:'K!I&4=>4G+;XNPJX:;&UTA*D-'&W>OX;7Y2\8P^OC.,X[X_P"W_'&?OC./
MUQG[XS]L^-%^^J&3[@7-89EF?OYF)J95D>Y58I3E5*GFL^Y&8AU9LS`S]00E
M,=&,RY>TCE_X.KYT_LN8^AJT-!!=0Q%F-"Q8\##^J.EV%C$S]3XS$3U'4>?$
M\3QXSGMC.<_I^GZYS^F,=^WWSG[8Q^N<]O%.^K-]>N<MX5COE&%?;MWRG"OY
MNW?[_P!'A4[XHCEA<:7J/1_#C7AD@,;R)EYNU[&:C'W1B9VCTF0A8>M4-[T_
ML3%W.^3HILF/YD8?14!0"4$`R!3"]:7'GYRCY8]>>E<9.+?("\Q'&/7>PJO6
M]@0-*E(9JFVNOZ3#*MN^IHTY,:>Z^#,SC9NMVSAI%#<A@6-:`6VHYIU5>OBF
MZ<MCE=PSO-K>E`==6/54]3I"1CL>5^/Q5=J`S-R(C7B$OA(E6JU=@31L.BJQ
MZ@+"R$%L(PTU?WMSP></W%X(O?93>[3Q7\KJYHBUCZI#0NV<U=U+%JZMK97F
MX*5D715Q@B[[CU3O-N5_JO"N6'CC86JCJ*P'7I(%I>)7*R+IUG"1Q\!"[\8V
ME$1(OF1_EWZ8]Z8/3ITCT\=#5FL0\779'>ED@HN1WAM0K,<39['<BPA7YFOQ
MTPOL9&4*M2'JQ59K83@X.!Q,S$DT9/24E($$VS)1F>_\/#^_;OG!H^,Y[?EW
MSA[&?M^GW^WA7&-^%JX@S0`<O$<K>49\5*"CR,6<-):H('-C3F4%@%L$(H"4
M/M$B/,O-O(2A#J%X6E*4JQC'V_M5?BE_I1<JO^<U7_\`@?"SK4^#;>C;U-7W
M/V+>A=<;K+W<'N29,*?L8B=V?C6N/V+4/0*6`K6(@(QZ-9MKEV51JY^=P#+K
M4ZJ@4A2N65X&`&!CRF8R/WF?V9L+LF',F<R4E/K57Q&W3NUB#K%/4,T/'`:_
MVQKVYU7\:GJ.@6'^L86QST?$5[:!"8AQA0VPZ+<WJ]E5E$9;D)6(DW29@I\N
MOQ1+1&:=RDEN9'00VEOJSDL%WFQ<'>1->V,^PQD9).PZ#0[S1[A(Y&PA#(WS
MR7@7I](XW<9E$LEIGLVC"4T&OWPS?`W6,`JR[0YM;VU_5E&"1BYZ^W'1M4K^
M3SU*2#'N2ECI\?&9+-<;6D01;^7B5MJPRVM2,]B!@\5M,\/>BURUU+H';DGN
M_5CO'7EQ<J[L.1GJA96I1=IH]M(E1HJ9HHHE8+C(^5%+%;S'MKR@I)B"G5E)
M=[,VCK\;M\9X5BU>0:7)M/#YE2C,U+N!9RHKXEKX_P`C)_(=:NPV$VE(<D9?
M!`F!2"A4@9]`Z6;NU]OE6I9QL_!HZO&+4WLZIL)T"=IH$_BTI2JO5E7R()B6
M3\,^;))A,DSF(I'\*-_%`Y(_UFF?[']<^*:=)O[?$4<\/]K\X?[>ZEXN7\*-
M_%`Y(_UFF?[']<^*9])W'?XB;GEC^66YPX_X[ZJ6/#3K?^Y?XA_[?\O!_P":
MCZ7<W_T7V4_^V+_Q,]>W7;V!M'G5U.>.W2_UW/.0]6K,QKP*39QEXN+3M+;$
M;FQ35]GP`T8R>/K#4)(Y44POU7`4R-K\CS&95U33:/$WB-HOA;IRMZ5T)3`*
MK6(407,K*)9979[S8$CH:D;G>IQ#31=AM$RZE9)996<#`H6W%PPD;#!@QXZB
MNV9`+1/Q4-4M6Q'&UU^\[-UPJ`DIY>&Q&$;;XW,ZOJ10C[SRFVV(R\O?)07%
MK;0R2RXGTV_+VR\"G_-3^GVQC./Y,X^V<?[L_;Q7_N78?G<7]L^.T#)."WAN
M?R!JTS()O;>HQS-!]CQZA[JYB,+AOE-:'F(>/G/;IP1*KV_SK;N`+-=7);F.
MLV]&VKE404%)29F)^);A(I*0\8=*X/\`</77Q2<7&S,<=$2X`<G%28A,?)1D
M@,R;'2`!C*QRPC@2D.B&!E,..,DBDLNL/M.+;=;6A2L9Z^'XAGIU53A3MRI;
M-T/&HI_'GD>Y8)$C6,*X2-4Z%N:F1><3"8.'P^L("%LU:GW)>N@MMX17WT6Z
M%B$AP"@(X7L+?"D/Q8^Q:V-HOBOJ91C"[?.;5O&QV0$/(42-5ZCKZ0JAAQ`^
M$J<:8,FKQ'AANK4VEYT0U+>'<CO99\_8K7U*'N)BTJ+&E4UBL5=*I$D275UT
M[%@7FO[&&4V)&PMW4&$"804`U@E[>[6;GW.%Z=JT"QLYT(L4K/T+5N*RA1)$
M_HI79`Y4Q7<@<R!2,FL)$EG(SE?*\,.B+3-W54EH78(W$CCS2-8O.*[+%V%L
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M37QJ^]&1PZOHT,^YHAFH59L6%UW:0$ZM:![EB()`85$K(0=!B:OMWG$E&8[?
MP\/[=^V<FCYSCO\`GVSE[.?O^OW^_@8?5'Z=6E^H9Q_M-;D8VN1N^:Q!24KH
M[:8[<>W9J_;P!""HNM2,JVM!LE1;45C$+8J^:Z2"TV<B=CAAYZ*C3&1=?M5?
MBE_I1<JO^<U7_P#@?'SF?"Q\1X\0D\_E9RB"""'?+,,+DM3#"B"C-+?())(>
MHB&6&&&6UO//.K0VTTA3BU)0G.<).33X-B:5/5RO<_7J7Z3UOK/5P>W!"P"B
M?$HC=Z8MD=K:HHD&KDUF)`4Q+5I6>7ZU&SG:'`,NQ3MI)+U,Y77(9`XB)*)+
M'GP,)GR6R.B68B8R)#W'X_"\\L+3?]$[DXBWZ4?)D^-T_#3VNPI)3[DE%:ZO
MY4XQ,5-MYQU:5Q],O\)+)"'PVWB,$LXT:/GV(P3`Q+>J)TXXOEM3G-GZR`!C
M>1-(AULQZE9P,)M&L`H)*Q0YMWS(89F6777'*58"<=@#77(61=1#2/N8O4'2
M8Z;/#;AKL/;6R>*7+:3Y'OVRDU^E7:)3>=,WB*K[&)YZR5Z5(?UC%L2$9(%K
M#EAP42)B0Y`19SB!B'A&WABT<A^0>IN+6GKOO3=UJ$I^N*%%_,IR5)0L@A]Q
MYYL.,AH>.8PHN9L$])/C1$#"A-N%RDF6.*RG&%+<;7/=-&'R_F>T.%2M.I;M
MBH::94'5;A:=JO7BQ**9#\P/?H$UZH@2(S='7D)^/J/G\6KZ_ML'&^<C5L55
M4["GV!N*>-6O48TJ5Q%^)(%6,](A`/\`J`E,BP27+!,#W"#JWS5"T]L?4?)2
MI[(OFZ]&5"T2&OH6&B7I#:FX4T<4MR0U.9#G8%(SMFM,`/MI<.6X=88&.D"R
M&#+#!FHF@_<,.+'(3K\<QK)S1Y?.2$5Q8ILVW#IB(DB0C8*9BX=]V0KW'O49
M+C&?\6(A)#16V;J,XW*FOR)7<INVV1#M=Y.J;/W!U?+[RFY+:8XU&ZKLVC)6
M'NM>L.MWR1,7.JL%,*AZU:YS,DPH[E558R/'OT/-T<<8>T5IHV`/`C9BOT.:
MMK`_2&YYT;=.O(OCC9(JI4#<%`C)$N(B*O!1M3K>RZY@MV3FK;"PL4*#%`77
M$K(G2NQ(0,5A9\F:7<0V,LR$N-$1,#DO(/9>YR+@VUF5Z_.+E>G6Q^6?F+LM
MIXUJJ-BU2K_"3$IV)!E99.AHO7,'!01A7:^H>)Z;M?9X]PCG&Y8T,*M-JQP_
M2=796J<[51?"*5?1<_HRT,V`8ME9DE^;$)B2:;56M`S-=KL#48"%JM6AHJNU
MJN10$'7X"#CQ8J%A(6*%:"C(F)C`FF0X^-C@V61`@A6FV!AVFVFD)0G&/$\<
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M5[_$3_QJOJSU\_Q7?E_J^?\`_GZ*]'R]^_Y?IV[]^W\WC8_\/>1^5P[?L^/?
MS\0Y?3[^_N2MHF([_P!^O]NY]:S]M;8J]KO;-<^,2',H;,]QWU_B#=B>_P#I
M_P!_K_OUUZ(CUS[$FURG%*<PI+BWZMNH9;N.V<J]K;*,UA.58^_EQA*?W/?M
MWQC/;OCOX`=X+MU.[%]4:]XAR_J>IYQ^1HWF[]__`$UWH*>W?OG\O-]O`B?&
M5>?(_%YAO5NNH1:6J(^_KPJUQZ^_^L3ZSO[XG#/=+E+(ZZ,L8OK[_JX]DS_^
M]^K"<2JF9>>4G'.I@,-$D3.[M9(RT^WAT?(D?;8N:DW"&\_98X\5&'$OI_5I
ME>.V?RSV$:?R^WY9SG./Z%9SG'Y_T^%-.ACQBDKUN^>Y+3T:ZBF:<`D*[4BR
M!\^VE]F6F-4$7D);B<M/_2%1-,=.4WW4-(6:'PG*7F7,(;,\./`Z3*^4ZRR)
M'\VQ)JB8Z[2H(6)?[]$SY>I_N,1,?4QZU!_#+QZSE\*O[%I9*GD6I+Z@E$C)
MY]!454NZF(F(;:F[X=_1*%;!F1.)E=/K9]&$SG`D/DOQH5$UWE?38@8&7B"S
M_I^.W;78%O#M=C7K!ZS`U;V/5E-8'IEJ,6,"<$XS7K#)1XD?`3,$,[C5\0AR
M@X0KC^,W4VXX[+L=EHP\="L7QYM%+WBN#"0H=HRX5^[.!U?:Y2QT#I!O5>LL
M#\^&8][($V*1(?F277?&O-B:CU7MV&57=K:VH6S*^K"\9@]@4^O7*([+QC"\
M8C[%'2(J/-VQWRVVC/?&,]\9QC/C1&+[AU9PZW%N:\?5RS#H2<Y+?RVY^WBB
MR8\U4=%0LDZL=1(TW#X?0+EGP*4H+2U.%V(U;'(.+;#./:UR!C07^.NYE:9!
MU`LMTF2(B_KZFRN9/^HH&&&;"`KCXGSINYBU2'R;DQ@M+B48A,Z@B?F"T9&R
M_DA)>+]F#P.AW&`E97*I(R0K#J!UA>8I(W>1G7FY8=0ER2XM=+GC7L^#E;N*
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M8=NC!TBXCIRZ\EK_`+*-C;7RHVQ!@`7V7BGLFUO7=79)3*,:RIASK+1$HWF0
M2-(W6U.I:Q:)L&/;!'8AH2/<,W?U?NG6)U&N*I^O:^1&0^ZM=RR]@Z0L$N\L
M:)Q:V8]^-E*A8BFF"71ZS>H1]Z'/*;9<^52K4#8%LDMPRQ7RK>)X3G\UY'8Y
M4',VWS+?7=5=79\8A:R3$`JL"8_8-,$#%;\;^@J_DL_+R*99U<6Q$\>+C"Z8
MCCG5.JQ'<^;(9^XWFW^HK)-_SY=/[H=$''7B,0DOP@ZW.[.F8!'\'NIIH?;B
M&-4#CUNAV\4,/&SJY307'PXF#DX>R2D9";5HT8.VT+1[S2[/G**R$)&--69A
MD4X<K$W\3/TQXF(^9!S&]Y\K([CR82,TM*A2*G4/*:0+DNQS,'`MO/-XP6VX
MN8]K@92?4?01W&P<;9>FM1[GA<5S;VK]>[2KZ596B#V)3*Y=(E"\J0K*V@+'
M&R(S*\J0A7G9;;7YD)SW[IQXK1"=,_IZ5R<>L<-PFXN!3+[V2%&8TAK]_P!-
M_)&"L.C#EP9`8BT/XPMO(H[/II_>V\):[MY<+G*/;/=L,U=KAFWGZU@Y=>3Q
MO<KHR+EH_P!SGA7O4GNHP]DD9)KF8A,_1&1$<K-7`YWDI#/S.3Y=S.0,*J,V
MLQS=&M7'Z6DG57K7:E00("QPP11'4P,=1"J>YMK\Q_B0-N:_U'I?4MCT-P2U
MK=46&S[&M:<R<=F02AR))N-CFVFF*M:-AQ5=.DQ=?:EI14RW$2$R=)6BRJ!=
MS+Q+-W*[3]"X]]*3DKI36<4W`:^U7P<W+2*K'J4QA8\-7M-V,%A\\AIH=HF1
M-RTY(2YZFT*.DRC#7?WQ]>?!"8J(A*Q$!Q,+'1<!!0X:1@(V,##B8B+`&1G*
M6`PA&A@0!&&\9[-,-,LMHQG/EQC'?QPY4W1[)3)27+DJQ8:$;#R^9<]PJ*G*
MJ;!#CE-3:3GDK-B38UL9@QF2;=R^-Z39#)*,X2XC`7;YV&@[C]+-R48?&.,V
MQNYN'7LLL,:[\A3K5W0ON&&7+]CP@)L&H5UUE\:EB,G+"69Q:*"MEVCJEI[V
M]3:J[J6%+0(5UIE*TTZ8'(5J566B1`)S)G(FT_*1\5BOA0W6G.'_`"1RTZT[
MC')IG&<M.MNXQG.GM<YQC.6U*QC/;[]L]L]OOV[>*9])EYA7Q%7/%"7V%N)E
M^<.%-H?:4XG*=]U'S84VE>5X\OY*[IQY<_97;/V\.*Z55I.2HD;;-`CZZ5KN
MY>>;BYK6$;7P*Q8LM+5%+E&'JX((#(N(4`H!1>4N.8P)[?U/*SA*<AB-8ZWK
M]DD+E!4"DPMNEE'JE+1$U.OQMBDE2A""Y)1\X%',2IF9`IMLD[));N2R&T/$
M9<=0E6"]KW,KW-'W&T@RCA?/LP:2`BZ!QGQYUS%Q,BOXVQF$_4!"8F"[@OK[
M%T>$Q&;P-2=5+U<5L#?&PI7FK22P)E<I(&D("8&)BR":!1,2/<3$^@`]>OI0
MWWF=7*7R;XSBX)Y*:0A2(HVJ!&(AIK9VO03B++%`U.5QZ*6MD4:Q.%RM,8+-
MCF9827F(MF1'EVX)MZG_``V^)<A]=5UC2/4AU7M.J;EUZA%7G=BU2HI?D)XZ
M)3[-\C9NJI@BM6RDW/S,X3-J@@YJ)EI)Q\YJ*K:'<`);W_/\_&CML<9..F^<
MC*W;HC3^W'`D.M@O[)UO4+H4"AYE0[N`C+!$'F">=E>6\^W?;[8\N4]LH1E,
M7(YUE.X_4XIS7!9OY68QS,30HWOT[;Q8LEYV*Z'DEZ;=1I]%%:R$`N>I[.%5
MQ3,TN):"MFSR'BNN&/H7P6&K3MU?S,K4E,0*7M4)K97LK'L?G3,D<3,3XR;"
M,#>X?BA>"52K12].TO=^Z+Z4SZ5?K3U.:UG`D23J6\#CS-EM)[\F&PMYW+.5
M5^IV<];K2VQP7/48<6LUU4ZAS<VW2*1U%.=(^=:SW(6\2VL]*:+.`+@W:#IV
MIT@RXQQ@T),%KE:K#2$G(/?+(F?0FWV,U^=NUC8CFI:$#<[`K4_!+A?HN7'L
M6G^*V@-=6,0CW0=DJFJ*7&6,)_+>&LK!GT1"I@'/DQY>P9K&,>9><8[N+RJP
M%NU[0M@#!AWNE5*Z"1[[I(`MMK4)91PB7V<CO$",S8)S8S[S&<L.O,I0XXUG
M+:U*1GR^&#CON3Q'A&M4N\2XC=@?,AT]#;U$V]BS3E91^!1E-,:68HW_`!-L
M6%H;8L+#X))83WZ$;'!^1\JS[%7DO(JQ?M&:%++I-K9Z+0F$Q<MR;BLWF"OY
M!4EABE1G\D0<_P`J?Z;TY1>0_38TQI'9$?\`-Z'M;AIJ:D649E3*2<Q5ATU6
M`G#8PEUHAH65CG'&92&/PTYD*4##,;QE;*<^%(]3[4YR?#@[VO.M]JZUF-X<
M+=CVC,D!8H_W4-3[66@=@2-V!0;@Z)(P]%VJB"8#B[YK:UY8#GE1S"&"%!@P
M5PR^$""%&!"1L<(*!'QXHX0((0[(@808C*!Q1!!1T-L###,-MLL#LMH99:0A
MMM"4)2G'QS<#"66*.@[%$1<]"R@ZQ)*(F8\25BY$5S'9P8^./9(",87C[*9)
M8=;5COC*?OX4^-\ZC&G=SM/'1O\`%^1NE^EAVK#*Y`\&DRO=H7E`3*=^O!>,
M/!<PT8&"&"!1K8=OB,Z0Y%RAI-R-[#3":.JA(.$TRL`=5MU6%`6*CY")E1''
MA,E,=^1"0`:_\31TS)B":EI.2WQ5Y!3`[C]=E=-24E)#.NNJ;?8R?5YF>KK^
M1&TX*>>9FLL+&<;RPMTCU!FQR<R^MSM7J25^=X1]+CC_`+GG)G;H!%4O.R):
M/C8VT-4>5;4#9(J&B(:4F(G7L)-A/N1UAV1L"TPK</7WY)@**&.,8E@F2)3I
MC].Z9E1)J0X0\6'I$):7&'D:/U^*WYTDJ+\SP@<(.&3E1"U+7[H=["\9RVO"
MFNR/%IM=:FU=J"#36=4:XHFLZVG+:L0&OZC7Z;#>=I.4-K5&UV/CA''$)SG"
M7'&EN8QG/9?WSW+U^3>V>+87IXO#=N_J5V0^DGD>W7=D5+*Y@D.95H4T/O@D
MQ$XKV'K!D_3"F/N1KL+G>H@\_5Y-E5*#@^*TW%RW+T;"2B!:M;[3S53)HR0R
MU*R,.YD!B?OT,'II\*M6=(+A'.YVU=:5"V)YLO;W)C;11`\/3HZ2#BF0V(>.
ME#&!"E4RA0K#4%`+,0DR9DR):7&`&+L;<6TLSOC=7(SXC/G#`Z%T%\WHG#S4
MLIF;8/E!W$QU2J:GVHN9W;M`00@@*4V9:V/>1>J-?OOX=B1"%Q#*A?/L*QH>
MSM3-`LWDUY=6J?/?4@ZC&Z3:$0<K\]%B"635%(K,Q@CYH/&E#L%J?2`0T$0P
MT1E;3K3:TX)7C>/VKK\+I^IIU=0-C72"*NPNOZW'5JKV.RU^"=<CBK)B#APP
M'Y0"+=RX&N0<:>2+G+C.'$8RI.8>%[D#CZ>_RR_1'7YOJ&T<O8N6$Q2QK%N(
M!EI6=*"AUR%'*:0?,M590K4"C69C/?:XG6O4,?CR]1.7Q6BVM6O9RI\;6H8D
M$ULYMLG#X#882S8N`)]EK9+^OXY]<'Q6XMZ>X<:.I6@-'UQ-?H]-"RC+Y&6'
M[!:)XK"')NY7"58'&S-VVQF(]Y+RBVFT]\#@@,!Q0$<"*$GJD]/JT:YM;O.O
MB8B2KMBJ\RQ>MGUNH(=9EH*;CR&2,;=I`(;#B5);6ETC8L&VRL<D=PNR9$(%
M(LXY#'_CU6A#J%MN)2M"TJ0M"L84E258RE25)SC.%)4G.<*3G&<9QG.,XSC.
M<>*HWJL\B&R>D]SKEAYVYOF9';&Z92R;?RE/F3284DR9*)9$E$S'<3$[EW!<
M3EW'O\/V512&K"FXMVF$+LXEVL,13MT"&0E<I\1$UB0"Y/DHB'L3$3G!'JG:
M8Y&:D03N#8&N]6[@I:(N*OD=8K/!5>!LA!C)?R^WTMR4DTH)B9Q,>4X;$MNN
M%5N3:(`?]0!V)..G@BBM(Z;7V\VJ-:*[=^WFH-15V[]N_;O#9[=^V._\O;'B
M>(]56HFNI3[-6RU80!V"2U9-Z^H,@%I1!R/7E,3T11)1`^74?N/2YO0S*5+1
MU\+7N54"E^FW.O5FW9#L1>Y*[[%B\E^,.("@6M$VB"X.%C\&^=&:]Y'ZJMNG
MMGQ.92J6X#VSZV%(8E8>1'7@F)L,`<MMWY=/01[;,A%FX;<0A]KTB&2`WR1G
MDP>2'3RVWQ7WA2Z3L($ZP:DO.R:?5*QN"O".,P4U#V6W1<(H.4=2V0S3;PU'
MG.9=@I-66'C$^ZKQ4R!C*FGGO''RD3&383D=,1X,I'O.#.O`R08YX;RPRF31
M5.BE-NL.*'+'9)84MO*F"&FGVLH=;0M,+<X[3VQ6;)^&TGJ%6!&"[""\I4X)
MF(8J9[F([$@*9D2ZDQ->]R?:?!]QE5;%HIS]O/\`$:FHI0M^2M#)85"^B27^
M53(B,EQ\BVUF,-B6>#'I>EM8=@<?-+@;BU+I77FPZS(RVQHF*L-HO&WPKVR8
M'IZRWB,!1&0@FOJHJ*>E29@DHEYR4/PRVVT-A+N4Y?R*CZ_S_A$OJGUNW^1;
MY?Y_-GMV^G?2[>;'W[?IV_Z_IX9PN'0)F+7;[;:L<O%`_5%LL]GP%G2F"LA8
ML<](S?LLE9V>SDG(GO\`V^2<LLY(RWE[+365^FG2/[6DD?Q6_%']FM_"?I_Y
M!\M_`)/?R>T]IZ_O?Q<[]^W[KTO;?S>I^OC7_#.1^TW$LRYFYNFO.JV,NZB*
MR\[=:,6KL(EL014FS$&:YF?WPN)[F)CN?)9N<0Y"E&10Q^.HI9^7LUKB:M1^
M75KH0MUE[26D+*Q\B;8-A1`^9F93U/?JL41LSCWO&'T5IW=6M]AV.1K-\G8"
MO6JC[A"HS+0FZ+O56SOF4$7KRTJD78@@,5P9;<J%@AO#K.<,Y=2XC7'&3IU;
M5Y5;SN-.I84I6M+479EOJMKW#-"*=C(R&J]ME8?,;7W'66A;A?"(X!I+<8#C
M(`!CR3[&_&@Y2T25.G]`J9JEOJ-J_9>J.^EK96+1['&E?:Y,^G)^.G/9I)QL
M][(V2_8>VP3Z+V1\N^MAIW*/(IB^,BHR%#;CHB/!BP&5D+9!CA!P0V5%$O%D
M9:%%;:8;R^2^\0\I#:<O/NN/.94ZXM6<]^Z?'N![VQFZG'7"TW,O6=\U(T$,
MO/.:D5!8=X5?&L1!\3%9?7C/CVN8$O7AH^S5'FNM1U.3T0S9I/\`EOC4"G%W
MD*QKU:]6M<OU6DQ=>JNI"S*8*P:6>"&H/MPZYTEI;7O'O6-3U'JZ$3!4ZGQ^
M`H]A;N2CSB'7%DR4U-'J2EV3G9H]U^2F)%U*5%&D.J0AEA++#6UO$\3P!6L%
M`"E@*UK$06`1`B`#$"(B,?4",1$1$?41'4>KZK5J].NBI40JM5JI77K5T`*D
MH0D(6I*EA$"M:P$0`!B!$8B(B(CU/$\3Q/'?U[^IXGB>)XYZYZGB>)XGCGKG
MJ>)XGB>.>N>M,\A8K84UIG8,;JVV0-(NS]?)5%V2RU==RA@A1\I(FV"J\W*P
MJC%R<&U(Q8CWS!K$>68Q(*:+2+D-\4O2_B+^!TP):0G[17I2@RVN]M.:OJ<5
M5LPLO2@@R]ECV@:PSZ9,AJV/S<]WE(\AJ+A\1(>?EZDF*_A/@V$K',3$7(Q)
M*W6QI,`R/(6PI"'T,&C.BNJ94XVZA+J6W5*;4MMQ.%X3E2%IQE.:)\5.&-RX
MV:&O?':4WN1LO7\E&V"%U>T;KR&K)^MXJSLV54VT:9&S!;]Q?/E+`F5<=->C
MVQG1718]D,0O#0X>U4:>I5M`MIK'/T*ID+X%:V..JQ/FDFAYBR%N&2!9S\@I
M)D1"UFNO]S"NV>:8VU7KW7U5<6Y1CO:G1A-6K;NNQ[%";-%MU`N59"K=41HJ
MVI_+#/;;``J5K%8-NA]Q\V.,W3?X\\EZQL;62M(U.<J]3'T69K9LV8L5`FMC
M2]?D+1-[')G$2HMAE+$:3@&*@@08^/AOEQJB""FCA"B2<_N;-PTSM;2.@-?W
MZIZ5*V97IK85YW==*'.;.:HE*B"\@1H%<H,"R4J>LMCDQS@TK/0J,CT,,Y?<
M&07DX7,YCITJE>GU3."OXN>@JI9JW^4WZ)PY[_Z;V(N^9_Q1^J$8&]YA?RO_
M`.0O^AV]Y^^]_;8VYR5X@26YKQJ#=&K]NR^B]]:6'F8:L;!!K$9=H>5J-E':
M'L%4M-,F30`I:.*RWD@-Q!XS@C[Y.7<%86QD42G/UZU#\=!OB8I8D2)V888N
M4;!U4UBFRKX>ZXI$(6^LGO\`T&K.29"-0XOSW'XQ.3G6-42'CGMR$I=L#:L+
MOT[%I7-<_(:6M2_3^\U5%*5U=+)I%_3FWZCB.TJO'!+F7L[=@?)"AWZ9K^Q9
MG2`@LW2M[5.A6.@U+:M6GXV=(CBR*C8Q`EP]B@9&'4#,@`^8-WS92G"/026?
MP/34VYSJY0UJG<A=S;`U9'Z5D@+A70:!6]=9B[3=):*D'8YB^$SRS3&80(":
M8.B!8:.=PQ*!@*-(;9?4E1-O-!<8[SJ^.V_)[4Y"7O?&R=S$*5.V6Q"_3]-K
M$>/%F1<7#Z^UD#+'P-0CV$FN$2>(TE#LP^T-ZZFD"M=\HX=\=/V*''37F@\V
M[ZZS0V[`W]4_),5WYI\]M4S9N_R?YG,X$]K\WP'_`.Y$9>]O[CNWEWTFYU2I
MHRW.FVZU"D)OFZ(?`239MUBH*LPM[I=X5H:,S+7P7C,.<PCF6,N'A\M.WQ`M
MN_M#3S,_DK]$(TPKF^\>WELXU2V%U-30/0_'R/S0.2O:2V2D@OWK3'F=D-/(
M_J!<C:',\A;/%\J^/E2FM56N2%U_Q>H>KCM_$V&M5TW#*T;8V]!-M@:YM$LP
MAY<W'/G!BU]U@@11,<XEA]R\7-OEYN74_#'1F_=0#5:,V!M*W:&$>B)Z+78(
M+V^T*\1+FP+>'R@"&FW)!08#4MAQ!8POJ/);]97=.IC>E/M,*A;EX_TCF`=4
M>,NV[';;D7KY&FJI)7/$O:3DR.8*:V.Y,#2LI4V2A(MN1:&'CY26C17HY!$:
MDLA]W#>H_J2S4?IZ\8=(W^^8N\]!;_XYZXE;U!P0]/68#[JP5V/,BHALF3:C
M2X:#>!$#)=(*=)+C6Y0O&7R7FL"C_6JU38=8_+3$T#-)S9!D+MBYLE\)1;>0
MQ*V+A9KKTTR*YB:RB&/-'L3[BY&)SV_J_K=`#XPY]"RS8KV1J[B=*X3)SW!N
MZ;$"RE:JC5?5R\&F:ZI0S(J.4'Y&X_QCYG<7.1O&6C\DMH:UWGK3E'8Y37"R
MZ?K%&NI;5NS4QJ92(`BGQI8U5FJQ1#S<<R=,M)D7PF3#"&@"QV<&:HY1\^MC
ML\I]DZ"H6_-<<7JAI2OP*9>\6_3MJW7-[)V'984>?;KH<3!@EA5>IP09@0\M
M*/X:EW'U$OQ_S%M38P5G:-P3VK*;SU;N+DYRDF.0H7'UR:=TG4_PYK^OV(^:
MD1&HQFYWH^#D2L6NV#`MXPZ4R%&M%R(H,DI333;\<_DNUN%.QC=^6[D5QIY)
MRG':[[0J4-5-L1Q.MJYM*K7+-7&P#5[&Q#STE$XA+-$@82'B0:=,;>:;2M+#
M*GY),A,.OKE68*8N*5.@LQ0ZT+KT4HJ0+`BP-],]%>_S8#]16R$P40?C,5I/
MV<KGS,BTO/'D%2D?*JMA.9?VTW^31QT,,$VTCJIY/0+XV\CB+RT1RNO8BA#0
MA\),<LZM2G4'W;,=+/9_*B.B*_3]YZRL+=%.))K$F12YN5CK[5()RVP5;L:@
M)/,#9ZS81Y`$8Y:%AG$$(94MH9E/BPNXN3NV*9L3IL5R"/@6HODU:B8K:R"H
M!DI\X-K6D':$)@7U%(S`N?-3R5Y<:25G(ZD,=O*CS9V$1P;AIKAI<^(UVVWL
MW8"]@1<OFU;;N4N]8;D=:I:9%L29X<67+-#`BHJ7`CTQ%4&(1'!1`B8Y!'K/
M/G.:&K?3JW4]M+B]LC;O,:1VH-Q8EVG:54OP<K]0B7X%FO-0/MR"8BTOF/6@
MQH<)$C:Y3,JZ0!'""-Q[3SAII78E;817'_B'2=3(6U@NKKA+Z]^67S=$O'LG
M5"@#E`NAO@03/CU,^SJ/N/7C,5'ZIHG:P^"U;EM&CEU5Y^EE\F.WR>Q=4S33
M).OX;EU7,S%71N2AJ2/X_B(]'<EZOO61ZN'%E=3V;1X(B4U7LZ0UT_*ZT7-K
MI])B@0,;+K,VK%F$59I:Z.,RJX"?97#MU5!X[;L7,Y"RLNVM]V/*`]431.K6
MJUKLB,GN+6RK2]:SZ+#&;+CRXZV$",Q,+L%U.9Z'K!2$I>DJ\(O`!Y7F)>3E
MQ7VSCD-P_M6V=^Z(Y&ZTW:9I^_:6C+)6',.42$OD59J?;C`7;#$^SEY".1$'
MG1[4A%XE<8D<C-R#98@PYH#+SF:V;B^JQ<R=;<M/K;(>-?:9MVH_H3$!A[,K
MFTS;LQB?Q8_F[60L@8=P/B.Q"D^X\OJY-9[^GCU&C;6V[*UMB';E&X)E8$P9
M4$:D6)`3<1!*Y6X3"061+A0*^0``0F)XYO5+W(BJU;T#H>Y'&]\++--+ZUG"
M!6*.F2$OOL;7.J52\JP@JU9C:T4D4XLI0E:*1QFY><?+:[\HI?C#L[66G=><
M>MBS^GZ#7++K,.^2NX[W2QF2)Y^SV:6F`QZ?`29KK8$8_"B/D!CF#J.:P\.2
M4O;W*??O,/4W!F!VK#ZHC8'D2\_3HO:,'6XY_;L7J\`\PL.Y7F#AH(EWZJ!B
M6QA)``%TDL:.'ET*F'2FHLMU?!7GIX;+:N^_ICCQRSLNA*+R<D2;!MJ@HUK7
MKSVM,P,\!:+#0[)(34/(TLRQ`D/I*6(R22P0\I;)GHL1C,9O"[<*P9+BWKWC
M;J[<>U=.%ZG553Z%M&L6*0=MJ)VL9*6LVWI;/CL6Z*L3\A(DV.ODF!QQ;Y+:
MA\#H"&:QT77U)3?$XNC9-%H1?^<DDM<3SFN5%$F7XTBCH8DIIB,R(F+#[L+\
M:V7S::/)E.'D:=>SE[2EZ,<DSFT+N@[3>>4[C>:RP[](E&;(+`VLP%KDEHL*
MLV(_5:@W=/\`/K>ALC<&JUR\X1<AJLPW678V6W5F8X@[&J\B4)(YFX.8UZ7%
MN,%L>X:8]H<-)2>6U#DX>?9P0T.W/&V;YT?6^0MVDMC\K>2=BV=='8F&@8F1
MUQJR@Z:#$C(MV4(>5,`1^+*BP2AI$EC.9,AP8A@<9H7'JCI';%GB`"N4`/B"
M9D((_&6Z0`R1DRF/(61I&/U,=05ZS,#U'G']`J]>E[T(7*JU%AUP:_X"O\L2
<BV2BL,)<N38_Q8]7[9CP4WD6J0+@1FQ'^BO_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
